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Abstract 
Atrial fibrillation (AF) affects one percent of the global population, and eight percent of 
Canadians over the age of sixty-five years.  AF is a common predicting factor for ischemic 
stroke and can cause a five-hundred percent increase in stroke risk.  This study aimed to fill a 
gap in the current literature by investigating a demographic that have not been studied and 
explored how healthcare providers can improve uptake of preventative measures against stroke. 
This study investigates the understanding and management of stroke risk in patients with AF 
living in northern British Columbia through the use of in-depth, semi-structured interviews, 
using a qualitative-descriptive design.  The sample in this study includes twelve participants 
from three communities in northern British Columbia.  Data was analyzed thematically using 
NVIVO 11 into three separate themes: Living with AF; Stroke Prevention; and Navigation.  
Results from this research highlight the importance of people diagnosed with AF taking oral 
anticoagulation and providing education about their increased risk of stroke.  
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Chapter One 
Introduction 
Atrial fibrillation (AF) is the most common, sustained cardiac arrhythmia globally, 
affecting approximately one percent of the world’s population overall and eight percent of 
Canadians aged over eighty (Assiri, Al-Majzoub, Kanaan, Donovan, & Silva, 2013).  According 
to the Heart and Stroke Foundation, over 350,000 people are known to suffer from AF in Canada 
(Heart and Stroke Foundation, 2014).  Likewise, in the United States, patients with a diagnosis of 
AF aged sixty-five and older make up seventy-five percent of the patient demographic (Cohen & 
Naccarelli, 2008).  AF was once considered a benign condition, but is now seen as a significant 
public health issue as a result of the profound impact upon mortality and morbidity.  For 
example, AF can give rise to cardiac failure, enlargement of the left atrium and stroke (Fuchs et 
al., 2012).  Ischemic stroke is of particular concern, with AF causing a three to five-fold increase 
in the risk for stroke and accounting for over twenty percent of all ischemic strokes (Kamel et al., 
2016).  AF-related strokes are also more likely to be fatal and are associated with greater health 
care costs and poorer health outcomes (Atrial Fibrillation Association and Anticoagulation 
Europe (UK), 2011). 
AF is characterized by an irregular and erratic heart rhythm.  Patients with AF require 
ongoing management to control and manage symptoms, reduce the risk of stroke and improve 
outcomes (Banner & Lauck, 2013).  For the most part, this management involves both 
community-based providers (such as family physicians and nurse practitioners), as well as 
specialist providers (such as cardiologists or electrophysiologists).  Patients require assessment 
and ongoing monitoring to optimize outcomes and reduce potential side effects.  Patients living 
in rural and remote areas of Canada lack ready access to many of these healthcare services, with 
  2
many patients being required to travel across large geographical distances to access monitoring 
and specialist support, sometimes at the cost of their lives (McGregor, Hanlon, Emmons, 
Voaklander, & Kelly, 2005).   
The term “rural” is difficult to define in relation to health policy and research according 
to Hart, Larson and Lishner (2005).  As a multifaceted concept, the term is based on unique 
landscapes, low population density, distance from urban areas, unique cultural landscapes, and 
economic activity (Hart, Larson and Lishner, 2005).  With regards to the phenomenon of study, 
defining the term “rural” means examining factors such as distance to higher level of care, access 
to primary health care, and resources available in the patient’s community (McGregor et al., 
2005). For example, some communities in the northern British Columbia region require a 
commute of over one hour to access primary healthcare, and even more to access acute or 
emergency care facilities (McGregor et al., 2005).  Stroke prevention is of particular concern 
with anticoagulant therapies that require patients to access regular blood monitoring or follow 
up.  As such, there are concerns that patients with AF in rural communities may not have 
adequate strategies in place to manage their risk of stroke. 
Rural areas of residency can be considered a factor in accessing health care facilities 
(Gage et al., 2000).  This can be due to the geographical location from hospitals, tertiary 
hospitals and health care facilities, and lack of medical staff or specialists.  For Example, the 
Northern Health Authority serves approximately 300,000 people and employs 7,000 health care 
providers in many rural and remote communities ("Northern Health Regions," 2013).  This area 
makes up sixty percent of British Columbia’s land mass and is the largest geographical health 
authority in the province (McGregor, Hanlon, Emmons, Voaklander, & Kelly, 2005).  The 
literature states that rural areas of Canada are, for the most part, at a disadvantage in health care 
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in comparison to their urban counterparts (Halseth, Helm, & Price, 2011).  Halseth et al. (2011) 
refers to the access to health care in rural areas with the “Rural Care Index” tool (Halseth et al., 
2011, p. 134) with which the distance from the basic referral center (kilometre per one hundred) 
multiplied by the population size (number per thousand).  This number can help researchers 
understand which communities have inequality in their access to health care.  Emergency care 
access is an important factor of health care access in rural areas.  Nineteen facilities in the 
Northern Health Authority are available twenty-four hours per day, seven days per week with on 
call Emergency care (McGregor et al., 2005).  According the rule of the “golden hour”, which 
gives emergency responders such as paramedics one hour from the patients calling for assistance 
to delivery at the health care facility, Northern British Columbia falls far behind other health 
authorities in meeting this goal (McGregor et al., 2005). 
 These factors can decrease their ability to achieve good health outcomes and may further 
restrict access to regular follow up with their family physicians, as well as access to other 
supports including pharmacies and medical laboratories (McGregor et al., 2005).  This study 
explores the experience of patients with AF who live in rural and remote areas of northern 
British Columbia using a qualitative descriptive approach.  This study aimed to understand their 
perceptions of stroke risk and their decision making regarding stroke risk management.  The 
study was guided by the following research question and sub-questions: How do patients in rural 
northern British Columbia with AF understand and manage their risk of stroke?  i) What are the 
experiences of patients living with AF and risk of ischemic strokes secondary to AF in rural and 
remote areas of Northern British Columbia?  ii) What factors influence patients’ decision making 
around stroke prevention? 
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In the following sections, a discussion of AF and its management will be presented.  This 
will be followed by a review of the contemporary literature related to patient experiences of AF 
and finally an overview of the proposed study, including a discussion of the methods and 
methodology to be used in this study.  Few studies have explored the patient experience of AF 
and even fewer in relation to stroke risk management and the rural context.  Understanding the 
experience of patients, particularly in relation to their perception of stroke risk and decision 
making regarding stroke risk reduction will contribute to existing knowledge and will provide 
much needed insights that can be used to improve the management and support of patients with 
this serious heart condition. 
Background of AF and Stroke 
In Canada, over 350,000 people are known to have AF (Heart and Stroke Foundation, 
2014).  Rates of AF rise dramatically with age, with five percent of the population aged over 
sixty-nine and rising to eight percent in those aged over eighty years  (Hardin & Steele, 2008).  
Many cases of AF are found by chance or following a serious complication related to AF, such 
as stroke, and many more individuals live with AF undetected.  Each year, heart disease and 
stroke costs the Canadian healthcare system $20.9 billion in hospitalization, physician services, 
lost wages and decreased productivity, money that the Canadian taxpayers cannot afford (Heart 
and Stroke Foundation, 2014). 
   AF is one of the most common causes of ischemic stroke, with an estimated fifteen 
percent to twenty-five percent of strokes attributed to atrial fibrillation alone (Hardin & Steele, 
2008).  Stroke costs the Canadian health care system approximately $3.6 billion per year in 
physician services, lost productivity, and hospital costs (Heart and Stroke Foundation, 2014).  
This number continues to rise with an aging population and increase in cardiac disease and other 
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factors such as obesity and chronic disease (Heart and Stroke Foundation, 2014).  The following 
sections will explore the pathophysiology and management of AF. 
The Pathophysiology and Management of AF 
AF is a supraventricular tachyarrythmia that occurs when the electrical pathway 
originating from the sinoatrial node in the atria become uncoordinated (Cohen & Naccarelli, 
2008; Cottrell, 2012).  In a healthy, functioning heart, electrical impulses beginning in the sino 
atrial node of the heart (otherwise known as the heart’s pacemaker) cause a heart to beat at a 
regular rhythm between sixty and eighty beats per minute (Heart and Stroke Foundation, 2014).  
The heart pumps blood through the atria and ventricles, allowing the body to transport 
oxygenated blood to the rest of the body and deoxygenated blood to the lungs (Heart and Stroke 
Foundation, 2014).  During atrial fibrillation, the electrical activity is triggered from many 
different areas of the atria and causes fibrillation, causing the atria to inadequately empty of 
blood (Cottrell, 2012; Fuchs et al., 2012).  This pooling of blood in the atria along with turbulent 
flow, may in turn cause embolus formation, increasing the risk for stroke and atrial enlargement 
(Cotrell, 2012).  Clinically, the healthcare provider may notice a new onset of irregular heart 
rhythm upon a routine pulse check, or electrocardiogram, or following an acute event such as a 
stroke or episode of heart failure (Hardin & Steele, 2008).  
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Figure 1. Image 1: Thrombus formation in the left atrium leading to stroke during AF (Retrieved 
from: http://www.examiner.com) 
Types of AF  
There are four different types of atrial fibrillation that commonly classify this disease: 
lone AF, paroxysmal AF, persistent AF, and permanent AF (Cohen & Naccarelli, 2008).  
Patients who are diagnosed with paroxysmal AF have an increased chance of progressing to 
permanent AF, and conversion to normal sinus rhythm becomes less likely as time in AF 
progresses.  During this time, progression of irreversible electrical and structural remodeling 
occurs (Cohen & Naccarelli, 2008).  Treatment of AF is dependent on the type with which a 
patient presents and could mean receiving either pharmacological treatment or cardioversion 
(Hardin & Steele, 2008).  The type of AF is determined during a comprehensive physical 
assessment and history taking.  These are summarized in table one. 
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Table One: Types of AF 
Type of AF Clinical Findings 
Paroxysmal AF Paroxysmal AF is described as “recurrent AF that is self-terminating 
with episode durations of less than seven days” (Cohen & Naccarelli, 
2008).  For some patients, this type of AF can occur often or rarely, 
and varies greatly between each patient (Bloe, 2011). 
Persistent AF This is similar to paroxysmal AF in that it is recurrent AF with episode 
durations of less than seven days, but is not self-terminating (Cohen & 
Naccarelli, 2008).  This particular type of AF precedes permanent AF, 
and is considered an intermediate step in the disease progression (De 
Sisti et al., 2013).  Patients in this AF will commonly be treated with 
cardioversion to return to normal sinus rhythm, but will frequently 
return to AF (Bloe, 2011). 
Permanent AF This rhythm is long standing and now the normal heart rhythm of the 
patient.  Either cardioversion was not attempted or was not successful 
(Richards, 2012). 
Lone AF “Lone AF” is a term that was coined in 1954 by Evans and Swann, and 
is considered to be an abnormal or rapid heart rate without any 
underlying heart disease (Wyse et al., 2014).  Approximately thirty 
percent of patients with AF received a diagnosis of lone AF, versus 
that of three percent of diagnoses today.  Lone AF was originally used 
for diagnosing patients with AF that did not demonstrate symptoms of 
heart disease, but through increased knowledge and study on the 
etiology and mechanisms of AF, has generally become an outdated 
diagnosis, used interchangeably with the term idiopathic AF (Wyse et 
al., 2014).  Another phenomena involving cardiac arrhythmia is the 
holiday heart syndrome, which is an acute cardiac arrhythmia 
occurring with increased alcohol intake (Abdelaziz, Kamalanathan, & 
John, 2011).  This condition typically resolves after twelve to twenty-
four hours, but can develop into life threatening arrhythmias 
(Abdelaziz et al., 2011). 
 
Clinical Presentation of AF 
AF is associated with a wide range of symptoms, and can determine which course of 
treatment is provided to the patient (Gehi et al., 2012).  Common symptoms noted in Cottrell’s 
(2012) article include palpitations, shortness of breath, tiredness or fatigue, generalized 
weakness, poor exercise intolerance, dizziness or light-headedness, an irregular pulse.  These 
  8
symptoms can be precursors to more serious symptoms, such as chest pain, hypotension and 
heart failure that could possibly lead to respiratory and cardiac failure (Cottrell, 2012).  While 
some patients experience significant symptom burden, it is vital to recognize that some patients 
are asymptomatic and may not be aware of any symptoms or effects.  In the research study by 
Boriani et al. (2014), the researchers aimed to investigate clinical presentation, management and 
outcomes in symptomatic and asymptomatic AF patients prospectively.  Of the participants, 
16.7% of patients were fully asymptomatic.  This subset of participants were independently 
associated with male gender, age, and previous myocardial infarction.  In these participants who 
are asymptomatic, mortality at one year was two-fold higher than symptomatic participants 
(Boriani et al., 2014).  This research by Boriani et al. (2014) shows that AF patients who do not 
present with symptoms may suffer from higher rates of mortality. 
Causes of AF 
The causes of AF are varied.  Many factors are preventable, such as smoking and obesity, 
but some such as advanced age or genetic factors are not (Cottrell, 2012).  It is important for 
patients to know of the risk factors involved in AF, and to either prevent them or become aware 
of AF symptoms so that they may receive medical treatment as soon as possible. 
Primary Causes 
Primary risk factors for AF include advancing age; approximately eight percent of people 
over the age of eighty are diagnosed with AF (Hardin and Steele, 2008).  Other risk factors 
include obesity, smoking, alcohol use, sleep apnea, inflammation, latent hypertension, male or 
female sex, and stress (Cottrell, 2012; Harris & Crawford, 2009). 
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Secondary Causes 
Secondary causes of AF usually relate to a pre-existing cardiac condition, but do include 
other non-cardiac conditions (Cottrell, 2012).  Some of these secondary factors may include 
ischemic heart disease, hypertension, sick sinus syndrome, heart failure, rheumatic heart disease, 
a chronic lung disease such as asthma, thyroid disease, or acute infections (Cottrell, 2012).  
Recent studies have shown obesity to have a link in the increased severity and progression in AF, 
as well as a corresponding decrease in those same factors with weight loss, making this world-
wide epidemic worthy of consideration (Goudis et al., 2015; Nalliah et al., 2016). 
Other Causes 
Other causes of AF that are currently under study are the possible genetic connections to 
AF.  Recently, studies have shown that there are genetic factors that influence the risk of 
acquiring AF (Mahida & Ellinor, 2012).  Multiple loci of DNA have shown that certain genes 
encode risks for the pathogenesis of AF (Mahida & Ellinor, 2012).  At least twenty-four genes 
have been discovered as probably associated with hereditary AF, most of them related to the 
sodium and potassium channel genes (Hong & Xiong, 2014).  Hong and Xiong (2014) explain 
that AF from genetic factors can contribute to the difficulty of maintaining sinus rhythm after 
treatment; approximately forty to fifty percent of patients revert to AF after one procedure and 
approximately ten to twenty percent of patients revert to AF after multiple procedures.  Genetic 
testing is not recommended for prediction of AF, as information into genetic links is not concrete 
(Hong & Xiong, 2014).  However, family history of AF can be a predictor of AF.  Compared to 
the general population, family history of AF can mean a potential two-fold increase in risk for 
AF, and a 4.7 fold increase if a family member is diagnosed with AF before the age of sixty 
(Hong & Xiong, 2014). 
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Underlying Pathophysiology 
 There are multiple underlying pathophysiological processes that lead to the development 
and perpetuation of AF.  These include fibrosis, inflammation and electrical and structural 
remodeling, which will now be discussed. 
Fibrosis/Inflammation 
Fibrosis and inflammation related to AF in several different ways.  Inflammation is a 
common finding in patients with AF but is also known to be a predictor of the disease (Patel, 
Dokainish, Tsai, & Lakkis, 2010).  Over time, inflammation of the atrial tissue results in 
stretching and thickening, and ultimately fibrosis.  Fibrosis is a poorly understood process in AF, 
representing a remodeling and restructure of the atria (Jalife, 2013).  Seen in animal models, 
atrial structural changes have led to left atrium enlargement and persistence of AF (Jalife, 2013).  
Using C-Reactive Protein (CRP) (a blood test that screens for markers in the blood that indicate 
inflammation [Pagana and Pagana, 2009] ), baseline readings can predict AF in patients who 
have had cardiac surgery (Patel et al., 2010).  CRP relates to structural remodeling of the heart, 
specifically the left atrium, leading researchers to believe that inflammation directly affects 
conduction in the heart (Patel et al., 2010). 
Electrical and Structural Remodeling 
Stretching and remodeling of the heart tissue occurs even early in the onset of AF and can 
lead to increased atrial pressure and pressure on the pulmonary veins (Cottrell, 2012).  This may 
cause concurrent heart disease that is commonly seen with AF, such as valvular disease and heart 
failure (Cottrell, 2012).  Cardiac remodeling is seen in patients with AF, as seen by “significantly 
dilated left atrium, reduced systolic and diastolic left ventricular function, and elevated systolic 
and diastolic pulmonary pressure” (Fuchs et al., 2012, p. 145).  These occurrences can increase a 
  11
patient’s risk for decreased cardiac output, which can in part cause cardiac failure and decreased 
haemodynamic stability (Fuchs et al., 2012).  These lead to an overall worsening of a patient’s 
ability to cope with AF. 
Cycles of AF 
Comparatively, cardiac cycles of AF and normal sinus rhythm differ in several ways.  
The heart uses both electrical and mechanical functions to effectively pump blood throughout the 
circulatory system of the body (Harris & Crawford, 2009).  The heart will follow a pattern of 
depolarization and repolarization, producing the waveforms seen on electrocardiograms (Harris 
& Crawford, 2009).  If normal sinus rhythm is occurring, the heart will follow a regular pattern 
of contractions with electrical activity beginning in the sinoatrial node (Harris & Crawford, 
2009).  AF, on the other hand, acts differently.  Rogue sites of electrical activity, known as 
ectopic beats, occur in the atria as well as the sino atrial node (Harris & Crawford, 2009).  This 
in turns causes the atria to fibrillate, due to the extra electrical activity depolarizing the cardiac 
tissue (Harris & Crawford, 2009).  These ectopic beats cause tachycardia, and an irregular 
arrhythmia, and decreased cardiac output (Fuchs et al., 2012). 
Risks with AF 
 AF was once considered a benign disease, but more recently it has been recognized as a 
serious health condition as a result of health risks associated with it (Heart & Stroke Foundation, 
2014).  Health risks such as haemodynamic dysfunction, thrombus formation, and ischemic 
stroke will now be discussed. 
Haemodynamic Dysfunction 
One of the main concerns with AF is the potential for haemodynamic compromise, 
stemming from the inadequate ventricular filling and atrial emptying of blood (Richards, 2012).  
  12
Several clinical findings can be observed by the health care practitioner in the event of 
hemodynamic instability, including hypotension, sweating, decreased level of consciousness, and 
cold or clammy extremities (Richards, 2012).  These clinical manifestations are signs of 
decreased cardiac output and reduced diastole filling time (Richards, 2012).  For patients with 
uncontrolled AF, this dysfunction can lead to a rapid deterioration in the patient’s condition, 
potentially leading to cardiac failure and death (Richards, 2012). 
Thrombus Formation 
Thrombus formation is the number one major risk of AF.  AF is known to cause a three 
to five fold risk increase for risk of stroke and poorer health outcomes overall (Kamel et al., 
2016).  Thrombus formation in the atria is a direct result of the decreased ability of the atria to 
fully eject blood from the atrium chambers, therefore causing pooling of blood in the atrial 
appendage of the left atrium (Cottrell, 2012).  Virschows’ triad of endothelial damage, blood 
stasis and coagulation properties outlines the main factors in thrombus formation, particularly in 
the left atrial appendage (Iwasaki et al., 2011).  Left atrial thrombi that occur during AF consist 
mainly of red blood cells and fibrin, and according to the literature respond more effectively to 
oral anticoagulants than antiplatelet medication for stroke prevention (Iwasaki et al., 2011).  This 
can be the cause of systemic emboli if dislodged, leading to ischemic stroke in these patients 
(Richards, 2012). 
Sex has become an increasingly important factor in assessing the risk for AF.  In another 
study comparing the risk of stroke between people with AF and without AF, females with AF 
had a significant increase in the risk of experiencing a thromboembolic event versus those 
without AF (Chao et al., 2012).  This study identifies that those who are female are at a higher 
risk of stroke generally than men.  In one of the scoring systems for stroke risk, CHA2DS2-VASc 
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females score at least one, as female sex is an independent risk factor for stroke (Chao et al., 
2012).  According to Richards (2012), patients over the age of sixty-five with a diagnosis of AF 
can expect a five-fold increase in the risk of ischemic stroke, making the prevention and 
treatment of AF in this age group a vital strategy in preventing stroke. 
Management of AF 
 The management of AF is multifaceted and requires management of both the condition 
itself and the associated risks, such as stroke.  The management of AF is guided by a number of 
clinical guidelines and includes the use of pharmaceutical agents to restore sinus rhythm, control 
the heart rate and reduce the risk of stroke.  These pharmaceutical agents work to control either 
heart rate or heart rhythm (Al-Khatib et al., 2014; Chatterjee, Sardar, Lichstein, Mukherjee, & 
Aikat, 2013; Richards, 2012).  In this section, the key management strategies will be outlined. 
Clinical Guidelines for AF 
There are several Canadian resources for clinical guidelines related to AF.  The Canadian 
Cardiovascular Society is a group of multidisciplinary panel of topic experts who review and 
formulate recommendations for medical practice (Canadian Cardiovascular Society [CCS], 
2014).  The CCS also provides information for patients and their family regarding a specific 
disease.  From the CCS, there are a number of clinical guidelines, such as “Recommendations for 
Stroke Prevention and Rate/Rhythm Control”, “Catheter Ablation for Atrial Fibrillation/Atrial 
Flutter” and “Surgical Therapy” (“Atrial Fibrillation”, CCS, 2014).  Another resource for clinical 
guidelines regarding AF is the BC Guidelines (Guidelines and Protocols Advisory Committee, 
2015).  This is a group of British Columbia Medical Doctors who serve as an advisory 
committee to produce protocols and clinical guidelines in regards to different diseases 
(Guidelines and Protocols Advisory Committee, 2015).  From this website, several guidelines 
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can be accessed for AF treatment such the stroke risk assessment tool CHADS2 as well as 
CHA2DS2-VASc and guidelines for warfarin therapy management (Guidelines and Protocols 
Advisory Committee, 2014).  Main strategies for treatment and management of AF include risk 
factor reduction, prevention of stroke, rate and rhythm control treatment of cardiac arrhythmia, 
surgical treatment such ablation and management of haemodynamic risk (Chao et al., 2012; 
Iwasaki et al., 2011; Richards, 2012 & Wyse et al., 2002) 
Pharmacological Management 
There are two main treatments for patients with AF: rate control and rhythm control.  The 
selection of medication is based upon patient symptom burden, tolerance of therapy, objectives 
of therapy and patient preference.  Both have been shown to be equally effective in managing AF 
(Wyse et al., 2002).   
Rate Control Medication 
Rate Control medications aim to control the ventricular rate of the heart without changing 
the arrhythmia (Richards, 2012).  There are several scenarios where rate control medications are 
preferred over rhythm control; these include intolerance to rhythm control medications, attempts 
at controlling the ventricular response, and when the patient with AF is waiting for a procedure 
such as ablation (Richards, 2012). These medications include beta-blockers or calcium 
antagonists, such as metoprolol or diltiazam, with digoxin as a second line treatment (Richards, 
2012).  Both of these medications are generally well-tolerated by patients. 
Rhythm Control Medication 
Rhythm Control is aimed at converting the patients’ arrhythmia from AF to normal sinus 
rhythm through the use of antiarrhythmic medications such as amiodarone or flecainide and 
sotalol (Richards, 2012).  These medications are ideal for patients with AF who are affected by a 
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high symptom burden.  Pharmacological cardioversion is most effective within forty-eight hours 
of AF onset; if the time frame of AF onset is beyond forty-eight hours, anticoagulation should be 
considered as clot formation may have occurred (Richards, 2012). In a review by Al-Khatib et al. 
(2014), the authors determine that in older patients with mild AF symptoms, there is comparable 
efficacy in the rate versus rhythm control medications. However, mortality rates steadily 
decreased after five years in the group of patients taking rhythm control medication (Al-Khatib et 
al., 2014).  Contrarywise, Chatterjee et al. (2013) support that there is a lower risk of mortality in 
the rate control group of patients. However, like Al-Khatib et al, Chatterjee et al. found that both 
rate and rhythm control medication provide similar prevention against thromboembolic events.  
Unpleasant side effects of antiarrhythmia medications, specifically amiodarone, are 
commonplace and can make patients reluctant to take them (O’Donovan, 2012).  Some of the 
adverse side effects of amiodarone include: bradycardia, hypothyroidism, corneal microdeposits, 
nausea and vomiting, acute liver disorders, tremor and ataxia, pulmonary toxicity and 
photosensitivity to name a few (O’Donovan, 2012; Siddall & Howard-Baker, 2011).  In addition 
to negative side-effects, amiodarone can cause drug toxicity and for this reason, the medication 
must be titrated to the lowest dose possible (Siddoway, 2003.  Blood work must be drawn every 
six weeks to monitor liver and thyroid function when taking amiodarone (Siddoway, 2003).  All 
of these medications require on going monitoring, which can add to patients’ reluctance to take 
them. 
Management of Stroke Risk 
Depending on the type of AF, and the presence of co-existing risks for stroke, patients 
may need to take an antithrombotic medication, such as warfarin, or target-specific direct 
thrombin inhibitors such as dabigatran, for the rest of their life to prevent stroke (Assiri et al., 
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2013).  Depending on their score on a stroke assessment tool, such as the CHADS2 or HAS-
BLED score (see Appendix C) patients will be prescribed a preventative medication to help 
decrease their risk for stroke (“CHADS2”, 2014). 
Assessment of Stroke Risk 
There are several different tools used to assess stroke risk in patients with AF.  One of the 
most common tools is the CHADS2, an assessment tool outlined by the BC Guidelines as the 
best practice for assessing patient’s risk for stroke ("CHADS2," 2014).  Criteria are used to 
assess for stroke from “Stroke Risk Assessment in Atrial Fibrillation: CHADS2 Score” (See 
Appendix A for scoring tool).  This tool helps physicians to standardize stroke risk assessment in 
patients with AF, and ensure that patients are receiving appropriate pharmacological intervention 
depending on their health history.  Another scoring tool is the HAS-BLED assessment (see 
Appendix C).  HAS-BLED differs from the CHADS2 in that it accounts for major bleeding risk 
factors, mostly in patients who take warfarin. According to the Euro Heart Survey, HAS-BLED 
is an improved scoring system to account for bleeding (Pisters et al., 2010).  However, it was 
noted that the presence of bleeding risk factors should not be the deciding factor in the choice of 
anticoagulation (Pisters et al., 20101).  Assessment of stroke risk is vital if patients are to be 
provided with effective stroke prevention management of AF. 
Stroke Prevention Therapies 
Pharmacological treatment options for stroke prevention are usually either aspirin or 
warfarin, or both as well as novel agents.  Health care practitioners need to weigh the benefit of 
each medication, determining the risk for stroke or bleeding (Assiri, Al-Majzoub, Kanaan, 
Donovan, & Silva, 2013).  There are newer target specific oral anticoagulants, such as dabigatran 
and rivaroxaban, in response to the short-comings of warfarin (Nutescu, 2013).  However, these 
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medications have the same risk for bleeding as warfarin, and because they are excreted through 
the kidneys, pose a risk for renal failure, particularly in the elderly (Nutescu, 2013).  It is 
important that patients understand the importance of compliance to whatever oral anticoagulant 
that their physician prescribes, as non-compliance may lead to ischemic stroke and possible 
decrease in quality of life. 
Aspirin 
Once thought to be part of the standard of care in thromboembolism prevention, aspirin 
has been shown to be ineffective in preventing blood clots in patients with AF (Deshpande & 
Wann, 2016).  This medication is an antiplatelet aggregate (Assiri et al., 2013; “CHADS2”, 
2014).  Aspirin works by inactivating the cyclooxygenase (COX) isozymes, which are involved 
in the process of thrombosis (Casado-Arroyo, Sostres, & Lanas, 2013).  Risks involved with 
taking aspirin include GI bleeds and major bleeding events (Casado-Arroyo et al., 2013).   This 
medication holds similar risks as an anticoagulant medication without any of the benefits, and for 
that reason is not recommended for the use of prevention of thromboembolism in patients with 
AF (Deshpande & Wann, 2016). 
Warfarin 
Warfarin is a vitamin-K antagonist with intrinsic and extrinsic pathways.  Though other, 
newer anticoagulants have been created with more specific pathways of anticoagulation, warfarin 
still continues to be a valid oral anticoagulant choice to treat the increased risk for stroke in 
patients with AF (Nutescu, 2013).  International Normalised Ratio (INR) is the laboratory blood 
test used to reflect the efficacy of the anticoagulation (Nutescu, 2013), and is advisable that the 
INR of a given patient with AF stays between a narrow therapeutic range of 2.0 and 3.0 
(“CHADS2”, 2014).  In the study by Kääriäinen, Paukama, and Kyngäs (2012), exploring 
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adherence to warfarin therapy, sixty percent of participants had INRs between 2.0 and 3.5 
(deemed the therapeutic range) leaving forty percent of the study’s sample not receiving the full 
benefit of this therapy.  In patients with non valvular AF, stroke risk can be decreased by 
approximately sixty-eight percent by taking warfarin (Jackson et al., 2004).  However, there are 
contraindications to taking this medication due to increased risk for bleeding events as outlined 
from the “Warfarin Therapy Management” protocol from the BC Guidelines (See Appendix B; 
Guidelines and Protocols Advisory Committee, 2014).  As for bleeding risks, one to two percent 
of persons taking warfarin experience major hemorrhagic complications such as intracranial 
hemmorhage, and five to ten percent will experience minor hemorrhagic complications such as 
hematomas (Sievert et al, 2002).  While warfarin offers good protection from strokes, it has a 
narrow therapeutic index and has the potential for many drug and dietary interactions, for 
example alcohol, medications, and certain foods rich in vitamin K can affect INR level.  Studies 
have shown that patients are in therapeutic range around fifty five percent of the time, and this 
can leave many people at risk of thromboembolic complication (Jackson et al., 2004).  Many 
providers are now considering the newer novel agents as a viable alternative. 
Direct Oral Anticoagulants 
Previously referred to as novel oral anticoagulants (NOACs), direct anticoagulants are 
pharmacological agents used in the treatment of AF.  These medications are direct thrombin 
inhibitors, including dabigatran, apixaban, rivaroxaban and edoxaban (Assiri et al., 2013; Assiri, 
2012).  These drugs work similarly to warfarin in preventing thrombosis, and are shown to have 
similar rates of preventing stroke and risk of bleeding (Assiri et al., 2013).  The difference in this 
class of anticoagulants from warfarin is the clotting cascade that they act on; warfarin acts as a 
vitamin K agonist while direct oral anticoagulants (DOACs) act on the factor Xa thrombin 
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pathway (Thakkar et al., 2017).  DOACs were created in the hope that a new class of 
anticoagulant medications could make up for the short comings of warfarin, such as negative 
drug interactions, narrow therapeutic window and frequent blood testing (Thakkar et al., 2017).  
These characteristics will help to make DOACs a more feasible anticoagulation option, as they 
will hopefully increase compliance for a longer amount of time and increase consistency in their 
treatment (Sattari & Lowenthal, 2011). Several studies have looked at the efficacy of direct oral 
anticoagulants in comparison to warfarin, such as the RE-LY (randomized evaluation of long-
term anticoagulation therapy) trial analysis looking at major bleeding event risks across patients 
with varying renal function (Hijazi et al., 2014).  The investigators of the RE-LY trial found that 
in patients taking warfarin, the incidence of major bleeding events increased in participants who 
have decreased renal function (Hijazi et al., 2014).  The incidence of major bleeding events in 
patients taking the direct oral anticoagulant dabigatran were much lower across all ranges of 
renal functions, showing that dabigatran can be prescribed to patients with compromised renal 
function (Hijazi et al., 2014).  While those patients who take warfarin need to monitoring their 
INR levels regularly through blood tests to determine a therapeutic dosing, patients taking direct 
oral anticoagulants do not require this level of monitoring (Hijazi et al., 2014).  Less testing can 
be positive for patients living in rural and remote settings where monitoring is less available or 
convenient (McGregor et al., 2005).  However, these agents may not be covered by usual health 
coverage and patients are often required to pay for these therapies if they do not receive special 
authority from their physician (British Columbia Health, n.d.).  This financial burden may be a 
barrier for some patients.  In addition, the initiation of prescribing this class of medication was 
affected by the previous lack of a reversal agent (Nutescu, 2012) which has been solved by the 
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discovery of prothrombin complex concentrate (PCC) and activated PCC (DOAC reversal 
agents) (Almegren, 2017). 
Invasive Management 
Three invasive procedures are typically used in the management of AF.  These include 
catheter ablation, surgical ablation, and removal of the left atrial appendage (Bloe, 2011).  These 
procedures are considered when oral medications are contraindicated or do not work, or 
cardioversion has been unsuccessful (Hardin & Steele, 2008). 
Catheter Ablation 
Catheter ablation is used in patients with AF to convert their arrhythmia to a hopeful end-
point of normal sinus rhythm (Park, Choi, Lim, Park, & Kim, 2012).  An electrophysiology study 
is performed on the patient to determine where the ectopic beats are occurring in the heart, and 
then those areas of tissue are in turn made electrically inactive through the use of radiofrequency 
energy, electrical energy, or freezing by a catheter delivery device through a major artery (Bloe, 
2011).  Eighty-five percent of catheter ablations successfully convert patients from AF to normal 
sinus rhythm for one year post-procedure (Bloe, 2011).  This number decreases to fifty-three 
percent five years after the procedure, requiring some patients to receive another catheter 
ablation to maintain normal sinus rhythm (Tidy, 2012).   Patients with paroxysmal AF tend to 
respond better to catheter ablation than those who are diagnosed with persistent AF (Tidy, 2012). 
Surgical Ablation 
Surgical ablation is similar to catheter ablation but occurs at the same time as other open 
heart surgery.  During cardiac surgery, an incision is made in the atria and a catheter is inserted 
(Hardin & Steele, 2008).  The catheter is then dragged through the atria while ablating to block 
the conduction of the unwanted foci causing AF (Hardin & Steele, 2008; Park et al, 2012).  
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Surgical ablation is effective in treating chronic atrial fibrillation when examining the longevity 
and effectiveness of conversion of the sinus rate and cardiac function (Lee et al., 2003). 
Removal of Left Atrial Appendage 
Thromboembolism resulting from blood pooling and clotting in the left atrial appendage 
accounts for approximately ninty to one-hundred percent of stroke in patients with atrial 
fibrillation (Johnson, Ganjoo, Stone, Srivyas, & Howard, 2000; Sievert et al., 2002).  This 
procedure, in which an occlusive covering is inserted via a catheter delivery device, occludes the 
left atrial appendage in the left atrium of the heart (Sievert et al., 2002).  This prevents the 
blooding from pooling and clotting, as the left atrium does not adequately eject all of the blood 
(Sievert et al., 2002).  This procedure is particularly appropriate for patients with AF who cannot 
take warfarin for extended periods and who have increased risk for thromboembolic events 
(Sievert et al., 2002).  This procedure can be done as a prophylactic, preventative treatment or as 
a therapeutic treatment in people with chronic AF (Johnson et al., 2000). 
Patient Education Needs 
In addition to medical management, patients with AF need to be educated about their 
disease to make informed choices about their health.  Patients need adequate education about 
medications and interventions offered to help prevent stroke, and the potential consequences of 
what their health outcomes will be if they refuse preventative treatments, such as warfarin.  
Howitt and Armstrong (1999) have found in their study that patients have a low uptake with 
warfarin treatment due to not only the patients’ preference, but also health practitioner’s 
unwillingness to prescribe warfarin. This shows that perhaps health practitioners may also need 
education regarding the prescribing of warfarin, in looking at the risk of bleeding versus the 
benefits of anticoagulation, and for teaching patients the importance of regular self-pulse checks 
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at home (Atrial Fibrillation Association and Anticoagulation Europe (UK), 2011).  Patients need 
to be educated on the seriousness of this condition; previously thought of as benign, AF has been 
the top cardiovascular related mortality in the Western world (Johnson et al., 2000).  Nurses have 
a key role to play in this process (Banner & Lauck, 2013). 
AF in the Rural Setting 
The ability to access and utilize health care facilities and programs is crucial in the 
treatment of this cardiac disease (Björk et al., 2013; Kääriäinen et al., 2012).  However, difficult 
access to secondary, tertiary, and sometimes even primary health care is a normal reality for 
some residents of rural northern British Columbia (McGregor et al., 2005).  As a resident and 
health care provider of a rural community in northern British Columbia, I see the experience of 
these patients diagnosed with AF have with dealing with their disease.  In addition to access 
issues, many rural patients experience more adverse social determinants of health, and poorer 
health outcomes than the general population (Canadian Institute of Health Information, 2006).  
An assessment of rural Canadians completed by the Canadian Institute for Health Information 
(2006) determined conflicting data; in the case of some chronic diseases, such as heart disease, 
the statistics were comparable to urban populations.  However, without including the issues that 
the social determinants of health show us, patients in rural northern British Columbia may 
experience a disparity in their health care experience in comparison with their urban counterparts 
(McGregor et al., 2005).  These patients are in a vulnerable position, and at times do not have the 
financial means to access health care from a tertiary hospital in an urban center.  This includes 
access to laboratory services, access to a family physician, cost of prescription medication, and 
sometimes lack of primary and emergency health care (Kääriäinen et al., 2012; McGregor et al., 
2005).  For example, in my experience some hospitals may not have base line staffing to provide 
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emergency care and may need to put a facility on diversion, meaning that the health care facility 
functions for a time as a nursing outpost.  This is of particular concern during medical 
emergencies such as cardiac failure and stroke which require skilled and time sensitive 
interventions.  Patients needing emergency care need to drive sometimes as far as one hundred 
and fifty kilometers to the nearest hospital when diversion occurs at their local hospital.  These 
are some of the issues that have influenced the research question for this literature review. 
Patients need to be aware of preventative risk factors that they can control, and be aware 
if they are predisposed to AF due to comorbidities or genetics (Cottrell, 2012; Hong & Xiong, 
2014; Mahida & Ellinor, 2012).  As discussed, there are many treatments available, including 
rate and rhythm control and preventative measures against stroke, such as anti-thrombotic 
medications (Assiri et al., 2013; Casado-Arroyo et al., 2013; Nutescu, 2013).  These treatments, 
all of which carry potential benefits and risks, are important for patients and their families to 
understand so that informed choices can be made in the decision of a patient’s plan of care for 
the best possible health outcome.  Stroke prevention in particular is of significant importance and 
further research is needed to explore the experiences of AF, perceptions of stroke risk and 
decision making about treatment options.  Understanding these critical perspectives can help 
health care providers when caring for their patients and can contribute to the development of 
more effective patient education materials, particularly for those in rural and remote 
communities who remain largely underserved. 
This topic is of relevance to nursing practice in that it seeks to understand the experience 
of the patient, and from there to improve health care delivery.  In looking at the most common 
sustained cardiac arrhythmia, AF, this topic can hopefully cover many common issues for a large 
population of patients diagnosed with this disease.  AF is not only worrisome as a diagnosis, but 
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also as a precursor for another common disease; ischemic stroke (Chao et al., 2012; Fang et al., 
2014).  By addressing some of the issues found through exploring patients’ experiences 
accessing health in rural northern British Columbia, comprehensive solutions can be developed 
and implemented to treat and prevent AF, and therefore secondary conditions such as ischemic 
stroke (Björk et al., 2013; Chao et al., 2012). 
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Chapter Two 
Literature Review 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world (diagnosed in 
one percent of the world’s population) and is associated with significant morbidity and mortality, 
including an elevated risk of stroke (Heart & Stroke Foundation, 2014).  Residents of many rural 
areas, including some of those in northern British Columbia, face many barriers to healthcare and 
are frequently forced to access health care outside of their communities (Pong, 2000).  In 
particular, exploring this with respect to the understanding and management of stroke is vital to 
optimize patient outcomes.  To understand the experiences of individuals living with AF and to 
underpin this research, a comprehensive review of the literature has been undertaken guided by 
the research question: how do patients over the age of sixty-five years living in rural northern 
British Columbia diagnosed with AF understand and manage their risk of stroke?  The following 
section will provide an overview of the search strategy.  Main themes that have emerged from 
the literature include AF as a risk for ischemic stroke, non-adherence to antithrombotic 
medications, and accessibility of health care in urban areas from a rural community. 
Searching the Literature 
 A comprehensive search of the literature was undertaken using computerized databases; 
CINAHL, PubMed and Google Scholar as well as resources such as the Heart and Stroke 
Foundation of Canada.  These databases were used due to their relevance of data related to the 
study topic, as well as the availability and size of articles.  Search terms for the literature 
included “atrial fibrillation”, “ischemic stroke”, “stroke risk factors”, “Northern British 
Columbia”, “health”, “health care access”, “non-adherence”, “non-compliance” and 
“anticoagulant”.  Articles were selected if they were relevant to the topic, published after 2005 
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and were available in the English language.  In areas where there were large volumes of data, 
such as drug therapy for stroke prevention, only key articles and systematic reviews that were 
most relevant to the Canadian context were selected for review. 
Government and organizations websites, such as the Canadian Cardiovascular Society, the Heart 
and Stroke Foundation and Guidelines and Protocols Advisory Committee, were also searched 
for relevant policy and practice documents, including clinical guidelines and treatment protocols.  
See Appendix E for number of articles available in databases in regards to search term used.   
The critical narrative review of the literature was guided by the research questions and 
was focused specifically around non-adherence and stroke prevention.  By finding a body of 
literature for this topic, a framework for further data collection and analysis was created and 
some of the known barriers to self-management were explored.  The review was undertaken 
using the following steps: 
1. Development of the research question 
2. Development of the research strategy 
3. Gathering, reading, and analyzing the literature 
4. Writing the literature review 
As part of this process, I worked with a health librarian at UNBC to ensure accuracy and 
completeness, as well as access all relevant literature in the review process. 
Search Strategy 
To undertake a literature review, a search strategy was developed to ensure that a 
comprehensive range of literature was found.  To achieve this, the search strategy, including the 
search terms, databases and eligibility criteria were identified during the process of the literature 
review.  The process of searching the literature was guided by the major themes related to the 
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research topic at hand, as well as the theoretical framework that helps to explain the phenomena.  
These helped determine the search terms and scope of the review.  A total of 512,272 articles 
were found, see Appendix E for a list of number of articles available from each of the search 
terms.  These articles were found with searches conducted between June and July of 2015. 
 Search terms were determined by deconstructing the research question into three major 
themes.  These themes included 1. Non-adherence to antithrombotic medication, 2. Accessibility 
of health care in rural areas, and 3. AF as a risk factor of ischemic stroke.  From these themes, to 
ensure that a full complement of literature was identified, a wide range of research databases 
accessible from the University of Northern British Columbia’s library website were used, 
including CINAHL, PubMed, Medline, and PsychInfo.  Additionally, Google Scholar was 
searched to ensure that all sources of relevant literature were captured.  To be eligible for 
inclusion, studies needed to be 1. Peer-reviewed, 2. Relevant to the Canadian context, 3. 
Published in the English language, and 4. Primary research studies or systematic reviews.  
Limitations on publication year were not included, as relevant literature spanned a large number 
of years.  In areas where there were large volumes of data, such as pharmaceutical trials and 
systematic reviews related to stroke medications and AF, only key articles that were most 
relevant to the Canadian context and self-management were selected for review.  For example, 
articles related to drug trials were not utilized in the review, as they have been reviewed and 
integrated into comprehensive clinical guidelines already.  Systematic reviews were included to 
increase the breadth of the literature. 
A Comprehensive Review of the Literature 
There was a large volume of clinical trials and epidemiological data related to 
pharmacological treatment of AF and the prevalence and impact of stroke, which have been well 
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researched in systematic reviews and meta-analyses.  The focus of this study is to explore the 
experience, understanding and management of stroke risk in patients with AF, rather than an in-
depth analysis of the drugs used to treat and manage stroke risk.  There were no studies that 
specifically explored experiences related to perceptions of stroke risk and patient decision 
making.  As a result, we broadened the literature search to identify key studies that explore the 
uses and barriers of evidenced-based anticoagulation therapy and to explore the management of 
AF within the rural setting.  In doing this, twenty-six articles were chosen for this review.  
Articles were gathered and critically appraised and then organized thematically (Grove, Burns, & 
Gray, 2013).  The CASP tool was used to examine and appraise the articles chosen. Articles 
were chosen in regards to the strength of studies at hand, and how well they helped examine the 
research question.  How well the studies could be applied to the population of study, as well as in 
the Canadian context were important factors.  Certain phenomena under study (such as non-
adherence) were examined in articles that, although not focused on AF or stroke, still provided 
useful insight.  Three key themes were found and will now be presented.  These themes include 
1. Non-adherence to antithrombotic medication, 2. Accessibility of health care in rural areas, and 
3. AF as a risk factor of ischemic stroke.  Each of the articles chosen for analysis will be 
presented with a brief description of the study type, design, participants, aims, findings, and 
strengths and weaknesses. 
AF as a Factor for Stroke Risks and Outcomes 
A search of the literature in CINAHL with the Boolean phrases “atrial fibrillation” AND 
“stroke risk factors” yielded a total of seven hundred and sixty articles.  Articles were screened 
for relevance, duplicates were removed and the most relevant articles were chosen for analysis, 
including studies such as systematic reviews and population-based studies.  The study of 
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ischemic stroke is a well-established topic of research, so by no means was the research selected 
for this literature review exhaustive.  However, key studies were chosen for their relevance to 
illustrate the importance of AF as a risk factor for stroke and to best represent the context of this 
research project.  Of these articles, ten were chosen for review.  As previously discussed, AF is 
documented as one of the most prevalent risk factors for ischemic stroke (Bloe, 2011; Björk, 
Palaszewski, Friberg, & Bergfeldt, 2013; Chao et al., 2012; Fang et al., 2014) and is known to 
increase the risk of ischemic stroke or transient ischemic attack five-fold (Lee et al., 2010).  
Ischemic stroke can lead to life-long health complications, and implications for quality of life.  
An analysis of the articles shows that AF is a significant risk factor for stroke, as discussed 
further in this section.  Unfortunately, patients diagnosed with AF who also experience an 
ischemic stroke triple their risk of death within the subsequent two years and has a mortality time 
of five to ten years after the occurrence (Awadh et al, 2010; Fang et al, 2014).  Ultimately, stroke 
prevention in patients with AF is treated with antithrombotic medication is the main goal in 
preventative treatment (Björk et al., 2013; Chao et al, 2012; Fang et al, 2014).   Therefore, 
ischemic stroke as a possible consequence of AF is a major theme in this literature review. 
Fang et al.’s (2014) longitudinal study focused on determining the long-term survival rate 
of patients who have experienced AF-related stroke.  The researchers note that there is scarce 
data on this topic.  Utilizing data from a cohort of 13,559 subjects recruited from Kaiser 
Permanente Northern California health enrollment aged eighteen or older with a diagnosis of AF, 
there were 1,025 incidents of stroke during the six-year period that the researchers were 
collecting data.  In comparison with non-stroke patients, stroke patients had a median survival 
time of 1.8 years after stroke versus 5.7 years of non-stroke patients.  Analyses of data were 
conducted on SAS software, using the Kaplan-Meier curves for median survival time, Log-Rank 
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tests were used to compare survival of stroke and non-stroke participants, and “unadjusted 
hazard ratios were calculated using proportional hazards models, containing an indicator for 
patients with stroke” (Fang et al., 2014, p. 1034).  Patients significantly increase their mortality 
risk with an occurrence of both AF and ischemic stroke, tripling the risk of death with more than 
half of these patients dying within two years (mortality rate was found to be 72.8% [95% 
confidence interval 69.4%-76.1%]).  The subjects were characterized by demographical 
information such as sex, age, race and history of pre-existing medical conditions such as 
hypertension and/or diabetes.  This study accounts for variability in race by broadly identifying 
participants as either “white” or “non-white”.  Strengths of this study include the generalizability 
due to the size of cohort of participants, limitations as stated by the author include lack of 
measurement of the severity of the comorbid conditions, did not assess for anticoagulation 
control in regards to warfarin as a post stroke variable, and unmeasured cofounders that may 
have affected estimates of mortality risk (Fang et al., 2014).  As a suggestion for implementation 
in clinical practice, the researchers support the use of judicious anticoagulant therapy in patients 
with AF to prevent the occurrence of ischemic stroke. 
In looking at a patient’s risk for stroke in regards to the CHA2DS2-VASc score, Chao et 
al.’s (2012) cohort study of five hundred and nine males and three hundred and twenty females 
with AF explored stroke risk in patients that did not receive any antithrombotic therapy as 
prophylactic treatment.  The mean age of participants in both the control and study group were 
45.4 ± 12.0 years, with 61.4% of the participants identified as male.  All male participants 
without any risk factors have a CHA2DS2-VASc score of 0, whilst their female counterparts 
similarly without additional risk factors have a CHA2DS2-VASc score of one due to the female 
sex’s risk for thrombosis.  For each patient, ten control patients were age and sex matched who 
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did not meet any of the risk factors of the CHA2DS2-VASc.  Of the patients, 1.4% experienced 
an ischemic stroke event within a mean follow up time of 57.4+/-35.7 months.  The rate of 
ischemic stroke between the male patients and controls did not differ, however, in the female 
group, the patients with a CHA2DS2-VASc score of one had a 4.4% rate of ischemic stroke 
versus 0.7% in the control group, concluded that females are at a significantly higher risk for 
ischemic stroke.  This is a significant finding for the prevention of thromboembolism, as females 
diagnosed with AF are shown to have higher rates of ischemic stroke compared to men (4.4% vs. 
1.6%; P=0.014).  Reasoning for this difference between male and female is possibly explained 
by differences in hemodynamic factors in females, such as higher rate of von Willebrand factor 
levels, and that females with AF have higher levels of tissue plasminogen activator antigen, both 
of which affect blood clotting.  Statistical significance was set at P<0.05 and analyses were 
performed by the software program Statistical Package for the Social Sciences (SPSS) 17.0.  
Limitations to this study included a lack of personal health practice information about study 
participants, such as smoking behaviors and other risk factors.  Another limitation was that there 
was no differentiation amongst study participants who had either paroxysmal or recurrent AF.   
Chao et al.’s findings of women’s increased risk for stroke were further corroborated by the 
Framingham Heart Study (Framingham Heart Study, 2015).  These findings should impact on 
practice changes to increase education and support needs for women with AF to receive the 
appropriate preventative therapy against stroke. 
Björk et al. (2013) undertook a study to explore the associations between AF and stroke 
risk and benefits of anticoagulation.  In this Swedish population based cohort study, the 
researchers accessed health data from the Västra Götaland region of Sweden, which makes up 
seventeen percent of the Swedish population.  This cohort was first studied for estimates of 
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stroke associated with AF and other medical conditions.  Secondly, all stroke events during 2010 
were assessed.  The five-year inclusion period saw 66,292 people get diagnosed with AF with 
416,122 incidents being documented (6.3 occasions per patient).  This corresponded to 2.5% of 
the overall population.  Further, twenty-nine percent of people discharged from the hospital with 
ischemic stroke were identified to have AF.  In the group with the highest rate of ischemic stroke 
with AF (eighty to eighty-nine year olds), sample size of patients equaled 69,972 with 1,591 total 
events recorded.  This led to an odds ratio of 2.1.  A review of the findings indicate that the 
patients included in this study may have been undertreated with oral anticoagulants and 
experienced worse outcomes as a result.  The researchers highlighted that AF is more common 
than previously thought, and that risk for ischemic stroke increases significantly with age.  In 
Wolf, Abbott, & Kannel’s study (1991), the researchers determined that AF is an independent 
risk factor for stroke by utilizing data from the Framingham study.  Citing this study, Björk et al. 
found that the prevalence of hypertension in this study was similar to that of the Framingham 
study (with different hypertension parameters).  The findings of this study demonstrated the 
importance of the assessment and management of stroke risk.  A limitation of this study is the 
dependence on the validity of the diagnostic recording.  Therefore, understanding patients’ 
perspectives of stroke risk is critical to developing strategies to improve the uptake and use of 
anticoagulation therapies.  Similar findings related to stroke risk and anticoagulation were found 
in studies by Awadh et al. (2010), Bloe (2011), Björk et al. (2013), Chao et al. (2010), Gage et 
al. (2000), Kääriäinen et al. (2012), Sattari and Lowenthal (2011), Waterman et al. (2004), Wolf, 
Abbott, & Kannel (1991).  For example, Chao et al. (2012) explained that AF patients’ with low 
risk factors still may need to be treated with anticoagulation to prevent stroke, while Gage et al.’s 
(2000) study focused on the underuse of antithrombotic therapy in patients with nonvalvular 
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atrial fibrillation the prevention of stroke.  Supported by Gattellari et al.’s (2008) study related 
the reasons that physicians are hesitant to anticoagulated patients with nonvalvular atrial 
fibrillation, both Gage et al. (2000) and Gattellari et al. (2008) explained why many patients are 
undertreated or not treated at all with antithrombotic medication for stroke prevention.       
 In conclusion, stroke is a major health concern and risk for patients with AF (Awadh et 
al., 2010; Bloe, 2011).  Judicious and timely use of pharmacological treatment, especially with 
anticoagulants, is an important factor in preventing stroke and improving patient outcomes 
(Björk et al., 2013; Nutescu, 2013).  In addition, since females are at a higher risk for stroke in 
comparison to males, as accounted for in the CHA2DS2VASc scoring criteria, healthcare 
providers must actively screen for stroke risk and provide treatment as per the guidelines (Björk 
et al., 2013; Chao et al., 2012; Framingham Heart Study, 2015).  Furthermore, patients with a 
diagnosis of stroke versus those with a diagnosis of AF alone suffer higher mortality and poorer 
prognosis (Fang et al., 2014; Gage et al., 2000; Gattellari et al., 2008).  There is a need for 
adequate anticoagulation in patients with AF to prevent significant health issues such as stroke, 
with a necessary emphasis on health care practitioners promoting the benefits of these 
evidenced-based treatments.  In the next section, the importance of patients’ adherence to 
antithrombotic medications will be explored as a preventative measure against stroke. 
Nonadherence to Antithrombotic Medications 
When exploring the research literature relating to the management of stroke risk and 
treatment decisions, data emerged relating to adherence of anticoagulation therapy.  For 
example, when searching the CINAHL databases using the Boolean phrase “antithrombotic 
therapy” AND “nonadherence”, twenty-nine articles were found.  Of these, eleven articles were 
chosen and analyzed relating to nonadherence of antithrombotic medications such as aspirin, 
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warfarin and novel oral anticoagulants (Abraham & Castillo, 2013; Chao et al., 2012; Gattellari 
et al., 2008; Howitt & Armstrong, 1999; Kääriäinen, Paukama, & Kyngäs, 2012; Nutescu, 2013; 
Sattari & Lowenthal, 2011; Tulner et al., 2010; Waterman et al., 2004).  There is a large body of 
literature that has supported the use of anticoagulation in this population, and these are well 
integrated within clinical guidelines.  Two systematic reviews were included in this section to 
increase the breadth of literature searched (Chapman & Bogle, 2014; Ogilvie et al., 2010).  
Adherence was identified as an important issue relating to understanding the experience of 
preventing stroke in patients with AF.  
As previously discussed, anticoagulation medications, such as warfarin and dabigatran, 
are a common and evidenced-based treatment for AF (Nutescu, 2013; Sattari & Lowenthal, 
2011). A review of the contemporary literature and analysis of the research findings highlighted 
a wide range of factors that were shown to impact upon outcomes of AF, including adherence to 
prescribed pharmaceutical treatments for AF. This was a large focus in the existing literature and 
was revealed as a key theme in this review.  From the analysis, factors that were found to 
negatively impact upon adherence to AF medication included female sex, ages forty-three to 
sixty-five and over eighty, poor relationship with physician, limited access to health care 
providers, and rural residency (Nutescu, 2013; Sattari & Lowenthal, 2011).  Surprisingly, living 
close to a laboratory for blood testing was also found to be negatively associated with adherence 
(Waterman et al., 2004).  Furthermore, a patient’s health status was also identified as a factor in 
determining the selection and taking anticoagulation therapy (Hijazi et al., 2014; Nutescu, 2013).  
For example, a patient’s experience with a major or minor bleeding event is a known factor in 
discontinuing antithrombotic medication (Abraham & Castillo, 2013; Tulner et al., 2010) and 
some patients remain unwilling to take anticoagulation, in particular warfarin, despite being at 
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high risk of stroke. The systematic review by Ogilvie, Newton, Welner, Cowell, and Lip (2010) 
supports that patients with AF at a high risk for stroke are commonly under treated with 
antithrombotic therapy.  This systematic review identified ninety-eight studies looking at current 
treatment for stroke prevention in AF (Ogilvie et al., 2010).  Twenty-nine studies supported that 
patients with previous stroke/TIA should receive anticoagulation, whereas twenty-five studies 
stated that patients did not receive adequate treatment for anticoagulation.  Ogilvie et al. (2010) 
concluded that there is a need to improve therapies for stroke prevention in AF. 
In a survey study of one hundred and thirty-nine participants (n=81 males, n=56 females; 
mean age=69.5 ± 10.5) by Kääriäinen et al. (2012), factors relating to patients’ adherence to 
health regimens were explored, including adherence to INR testing, diet and exercise and follow 
up with healthcare professionals.  Using a descriptive cross-sectional design, the researchers 
created a self-reporting questionnaire to measure adherence and factors relating to it.  The 
validity and reliability of this tool were found to be high through a factor analysis, correlation 
coefficients and Lisrel analysis (Kääriäinen et al., 2012). In addition, a doctor and two nurses 
who work with patients on anticoagulation therapy on a regular basis evaluated the 
questionnaire, and one question was removed (Kääriäinen et al., 2012).  The authors found that 
patients who had good adherence with health regimens had better adherence with medication 
adherence, fifty-one percent of the respondents had good adherence with overall health regimens, 
and seventy-four percent of respondents had good adherence with warfarin therapy.  In 
particular, the authors noted that if respondents did not receive support from health professionals, 
only thirty-nine percent had good adherence.  Significant background variables that were 
observed to affect adherence included that women (n=56) were found to have better adherence 
(p=0.019) than men (n=81).  Likewise, those who had INR testing at every greater-than or equal-
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to two week interval had better adherence (p=0.029) than those who were tested at two to four 
week intervals and less-than four week intervals. 
With respect to adherence to anticoagulation therapy, Howitt and Armstrong (1999) 
undertook a qualitative study to examine whether the implementation of an educational 
intervention of an evidenced based treatment, antithrombotic treatment in AF, increased the 
uptake of this medication.  One hundred and thirty-two participants, out of 13,229 participants 
from an urban practice in South East England were recruited to this study.  Participants were 
screened through the medical practice’s computer database for a diagnosis of atrial fibrillation 
and had been prescribed digoxin, which was verified in the patient’s chart (Howitt & Armstrong, 
1999).  Those excluded were patients taking warfarin for another indication, and those unable to 
give informed consent.  The participants then took part in a qualitative study that included an 
educational intervention regarding antithrombotic therapy (Howitt & Armstrong, 1999).  All 
participants were assessed on their understanding of stroke risk and benefits of antithrombotic 
therapy, and then were given a structured education session on stroke risk and benefits of 
antithrombotic therapy.  Notes were made throughout the interviews on the participants’ 
comments.  At the start of the study, forty-three participants were already taking warfarin, and 
ten started after the interview.  Seven participants who were on no treatment started on aspirin. 
Unfortunately, Howitt and Armstrong’s findings showed that few eligible participants decided to 
start taking antithrombotic medication, even after receiving education regarding the benefits of 
this medication.  It was not clear from the results how patient education impacts upon adherence, 
as either patients do not completely understand the consequence of poor adherence or that they 
simply are not afraid of thromboembolic consequences.  This study was the first of its kind to 
explore the complexity surrounding patients’ nonadherence to warfarin therapy.  However, the 
  37
study fails to explain poor adherence decision-making by the patient.  Themes found throughout 
this study were that patients who did not take warfarin did not see themselves at risk for stroke, 
while those who were on warfarin did understand the risk for stroke (Howitt & Armstrong, 
1999).  Patients who were of advanced age realized impending death and sought to prolong their 
life with preventative measures, while others did not want to extend their life (Howitt & 
Armstrong, 1999).   
Further data were captured that explored the impact of patient education upon adherence.  
Chapman and Bogle’s (2014) systematic review included four randomized control trials and two 
quasi-experimental design studies with the objective of assessing the effectiveness, and short and 
long-term effects of self-management interventions on adherence to stroke medications.  The 
findings from the studies suggested that a program with education, problem solving, counseling 
and medication advice are the most successful at enhancing patients’ adherence with medication 
(Chapman & Bogle, 2014). 
Waterman, Milligan, Bayer, Banet, Gatchel and Gage’s (2004) sought to determine the 
“frequency and causes of aberrant International Normalized Ratios (INRs) in warfarin recipients 
and the percentage explainable by warfarin nonadherence” (Waterman et al, 2004, p. 1258).  
From this retrospective chart review, three hundred and forty-seven participants’ data were 
utilized, and from that 4,305 INRs were studied of which 1,002 were out of therapeutic range.  
The researchers hypothesized that non-adherence of warfarin was a significant cause of out of 
range INRs.  The researchers only recruited participants with a target INR of 2.0 to 3.0, but 
defined the range in this study as 1.8 to 3.4, as this range rarely needs intervention.  The findings 
of this study showed that warfarin non-adherence is the most common cause of aberrant INRs in 
patients who take warfarin, and aberrant INRs tended to be too low rather than too high.  The 
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most common reason for nonadherence was inconsistent consumption of vitamin K, 
misunderstanding warfarin dosages, and missing warfarin doses.  As well, predictors of non-
adherence to warfarin was seen in people under the age of sixty-five, over the age of eighty, and 
in those having a shorter distance to travel to the laboratory for blood work.  
Gattellari, Worthington, Zwar and Middleton (2008) explored the barriers to physicians’ 
prescribing of anticoagulation for patients with nonvalvular AF.  This article was chosen for the 
insight it provides about the barriers to stroke prevention, and how it relates to the non-
prescription of antithrombotic medications.  This representative national survey study was 
conducted in Australia.  Australia is similar to Canada in landmass and population, adding a 
benefit to utilizing this research.  One thousand randomly selected family physicians (FPs) were 
selected to participate in completing a questionnaire regarding adverse events of their patients 
with nonvalvular AF and their responsibility on the outcome of treatment.  The questionnaire 
included eight case studies to determine how each physician would hypothetically treat each 
patient.  Responses in the questionnaire to five statements produced a score assessing the 
physicians’ “decisional conflict” (Gattellari et al., 2008).  Findings of this questionnaire were 
that fear of bleeding events effected the family physicians’ rate of prescribing anticoagulation, as 
well as their anticipation of feeling most responsible for an adverse outcome (P=0.18).  Another 
finding was that for patients with a very high risk for stroke who presented with bleeding 
symptoms such as epistaxis or peptic ulcers, the physician would substitute warfarin for another 
treatment.  The researchers concluded that physicians appraise the risk and benefit of treatments, 
and implement interventions that will decrease risk of bleeding.  This study outlined a common 
fear amongst doctors of doing more harm than good with treatment.  I believe the researchers 
highlighted the need for primary care providers to follow evidenced based practice by assessing 
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each patient for the risk of thromboembolic events, as well as risk for bleeding events.  In 
looking at other factors that affect nonadherence to antithrombotic medications, there are many 
that may contribute to the underuse of this medication such as patient preference, age and gender 
(Waterman et al., 2004).  The limitations of the study by Gattellari et al. (2008) is that it may 
only be generalizable to Family Physicians and that the data was self-reported by participants, 
allowing for potential bias of results (Gage et al., 2004).  The researchers controlled for variables 
in respondent characteristics by recording a thorough account of each respondent.  Variables 
such as participant age, sex, location (urban or remote), hours worked, and type of practice along 
with other characteristics were compared.  In looking at other factors that affect nonadherence to 
antithrombotic medications, there are many that may contribute to the underuse of this 
medication such as patient preference, age and gender (Waterman et al., 2004).  A strength of 
this study was the researchers’ attention to addressing these characteristic differences in  
physicians to ensure a good representation of Australian physicians, thus increasing the study’s 
validity. 
 In conclusion, the nonadherence, or non-prescription, of antithrombotic medication is one 
of the most common factors related to stroke in patients with AF (Gage et al., 2000; Gattellari, 
Worthington, Zwar, & Middleton, 2008; Waterman et al., 2004).  The analysis of the literature in 
this review provides clear insight that antithrombotic medications are an evidenced based 
treatment and best practice for the prevention of ischemic strokes in this population.  However, 
the analysis highlights that there may be various factors that may impact upon the use of 
anticoagulants in patients with AF, including patients’ preferences, aberrant INRs and 
conservative prescribing from Family Physicians (Howitt & Armstrong, 1999; Gage et al., 2000; 
Gattellari et al., 2008).  In a recent study, the researchers discovered that patients taking DOACs 
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have a high level of adherence and preference for this medication, possibly changing how health 
care providers prescribe and manage patients with a need for anticoagulation (Bartoli-Abdou, 
2018).  Examining some recent research regarding newer standards of care in regards to 
anticoagulation, direct oral anticoagulants, are at the forefront. 
Direct Oral Anticoagulants 
 Unlike the vitamin-K antagonist warfarin, direct oral anticoagulants such as dabigatran, 
rivaroxaban, apixaban and edoxaban affect the factor Xa thrombin clotting cascade (Almegren, 
2017).  An update in the Canadian Cardiovascular Society guidelines for AF management in 
2016 had a particular focus on DOACs in the management of stroke prevention in patients with 
AF (Macle et al., 2016).  Unlike warfarin, DOACs do not require frequent monitoring, blood 
testing, or dose adjustments (Janzic & Kos, 2015). Janzic and Kos (2015) examined the cost-
effectiveness of DOACs (this class of medication was referred to as novel oral anticoagulants at 
the time this study was published) compared to dose-adjusted warfarin, the DOACs proved 
superior average survival when comparing a list of clinical parameters (for example, baseline 
rate of ischemic stroke, intracranial hemorrhage and systolic embolism to name several).  This 
study showed that DOACs are a cost-effective option for high quality anticoagulation when 
compared with warfarin (Janzic & Kos, 2015).  
 Lip et al. (2013) utilized an electronic survey based study, investigating European clinical 
practice regarding the reasoning of choice for oral anticoagulation for preventing stroke in 
patients with AF.  This study was conducted to explore health care providers’ decision to 
prescribe anticoagulation, and as a result of newer guidelines recommending DOACs as a first 
line medication, how much of a role DOACs held in the prevention of stroke.  The respondents 
consisted of health care providers from public and private hospitals, electrophysiology clinics 
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with AF or arrhythmia clinics, and ‘other’.  When asked for preference of DOAC, dabigatran 
was the preferred drug to prescribe for AF patients.  Overall, however, warfarin was dramatically 
preferred, at 73.3% of the respondents stating they would choose warfarin for their patients.  This 
survey, unfortunately, had a low response score, and therefore the insights from this study were 
limited.  The researchers recommended that there is a “need for greater adherence to the 
guidelines, especially since guideline adherent management results in better outcomes” (Lip et 
al., 2013). 
 In a review comparing the efficacy of three different direct oral anticoagulants 
(dabigatran, apixaban and rivaroxaban) against warfarin, Goette (2013) found that DOACs’ 
advantages include predictable outcomes in regards to pharmacokinetics and dynamics, less 
monitoring, no food interactions, and a stable dosing in comparison to warfarin.  Goette (2013) 
reviewed three studies of comparison between warfarin and the DOACs: 1. The RE-LY study 
comparing dabigatran with warfarin; 2. the ROCKET AF study comparing dose-adjusted 
warfarin with rivaroxaban; and 3. The phase III ARISTOTLE trial comparing dose-adjusted 
warfarin with apixaban in patients with non-valvular AF and a CHADS2 score of one or higher.  
The author described a “primary endpoint event” as a stroke or systemic embolism to be the 
measure of efficacy of the medication (Goette, 2013, p. 130).  Safety of the medication was 
measured by comparing the rate of major bleeding events between the DOACs and warfarin.  
The findings of the data showed that major bleeding events were similar between one-hundred 
and fifty milligrams dabigatran taken twice per day and dose-adjusted warfarin in the RE-LY 
study (3.1 % versus 3.4% per year), while primary endpoint events were 1.1% and 1.7% per 
patient per year respectively.  In terms of when one-hundred and ten milligrams dabigatran taken 
twice per day was prescribed in comparison to dose-adjusted warfarin, endpoint events measured 
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out at 1.5% and 1.7% per year, with major bleeding events significantly lower than the one-
hundred and fifty milligrams dabigatran taken twice per day group at 2.7% versus 3.4% per year.  
Similar rates of major bleeding events were noted in the ROCKET AF study between 
rivaroxaban and warfarin (14.9% and 14.5% per year), while prevention of stroke and embolic 
events were statistically similar at 1.7% and 2.2% per year, respectively.  Apixaban proved to 
have significantly lower rates of major bleeding events in comparison to warfarin in the 
ARISTOTLE study (2.1% versus 3.1% per year).  In the case of primary endpoint events, the 
group of patients taking apixaban had a rate of 1.3% per person, per year of embolic events or 
stroke versus 1.6% of patients taking warfarin during the comparison.  However, on this note, the 
results of each study cannot be directly compared due to differences in trial design and 
enrollment (Goette, 2013).   
To explore the complexity of stroke prevention for patients with AF in rural settings, 
literature was searched relating to rural healthcare.  This will now be presented.   
Rural Health Care and AF 
To examine the potential contextual factors that may impact upon oral anticoagulant use, 
a review of the literature relating to rural and remote healthcare was undertaken.  Using the 
search terms “Atrial Fibrillation”, “Rural health care access”, and “Rural health care”, seven 
articles were chosen from a cohort of five-hundred and fifty-nine articles in regards to their 
applicability to the issues that rural and remote patients face accessing health care, such as 
geographical distance patients need to travel for primary care, and health programs (such as 
cardiac rehabilitation) that are difficult to access from rural areas.  Only seven articles were 
chosen due to the limited amount of research regarding treatment of AF and stroke in rural areas.  
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As seven articles are a small cohort of articles relating to AF, articles relating to cardiovascular 
and chronic disease were chosen to give insight for healthcare in a rural context.   
While no studies specific to AF were identified that related to rural settings, the study by 
De Angelis, Bunker, and Schoo (2008) was chosen to examine due to the relevant data regarding 
rural patients’ experience in accessing a cardiac rehabilitation program in a larger center.  
Cardiac rehabilitation programs help patients to access health information for increasing their 
quality of living after discharge from the hospital.  This study may yield important insights into 
why patients with AF do not leave their rural community for treatment elsewhere.  The aim of 
this study was to “(i) identify local barriers and enablers to the uptake of hospital- based cardiac 
rehabilitation (CR) programs, and (ii) identify preferred alternatives for the delivery of CR” (De 
Angelis et al., 2008).  The researchers recruited participants that were patients, carers of patients, 
and health professionals that were referred to or working in five hospital-based and one 
community-based CR program in Victoria, Australia (which is considered a rural area).  A 
structured interview questionnaire was used to collect data regarding patient demographics and 
barriers and enablers to attending the CR program.  More in depth information was taken from 
select focus groups.  Data analysis was conducted through descriptive statistics, and key themes 
were taken from the data. Patient barriers to program attendance were recorded as petrol cost, 
distance, feeling too well or too unwell, and having a lack of interest in CR.  Enablers to CR 
participation included family support and easy access to transport.  Attenders to the CR program 
lived on average 15.4 km away from the program, while non-attenders lived on average 40.4 km 
away, showing that distance is a strong factor in whether rural patients participate in CR.  
Limitations to this study are listed as having under representation of participants who declined 
participation in CR.  The researchers suggest that alternative transportation options should be 
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trialed for these patients who decline CR to make participation a viable option.  This is an 
important insight for people living in rural areas with AF who may need to access a higher level 
of care in other towns or cities, giving primary care providers an understanding of the difficulties 
of accessing sometimes life-preserving treatments or consultations. 
Graves’ (2012) study evaluating cardiovascular disease in patients over aged over 
twenty-five in a medically underserved rural area of the state of Alabama, U.S., aims to help 
develop preventative and treatment programs in this demographic.  Using a descriptive 
retrospective exploratory design, the researcher conducted chart reviews from a cohort of one-
hundred and ninety-seven stratified participants.  Inclusion criteria of this study included the 
participants being aged twenty-five or older, patients who have already visited the health center, 
and a health center visit within a three-month time period.  Characteristics of the participants 
were compared, as well as analysis of the variables that contribute to CVD.  Data analysis was 
performed using SPSS and Chi-squared testing was undertaken to explore categorical variables 
in the data.  Data from this study showed that variables that perpetuate cardiovascular disease 
include smoking, hypertension, diabetes, dyslipidemia and obesity.  Obesity was found to be an 
overwhelming factor in 44.5% of participants, and forty-eight percent of the participants aged 
forty-one to fifty-five were seen to have dyslipidemia.  In a rural population, such as the one seen 
in this study, patients are medically underserved and disadvantaged when it comes to continuity 
of medical health care.  The findings of this study stated that decreased health care access may 
contribute to the excessively high rate of CVD mortality in rural populations.  Limitations of this 
study were recognized by the researcher as several issues.  One was that the nature of the sample 
may have skewed the results, as patients accessing this health center tended to be in a 
demographic that avoided routine health care and preventative health actions.  As well, rural 
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residents on average have less financial resources and medical insurance, therefore are less likely 
to request CVD screening.  This study relied on information recorded in the participants’ medical 
charts, therefore, risk to reliability lies in the fact that some of this information may be wrongly 
recorded.  Additionally, limitations noted by the author in this study included possible errors in 
recording data from patient charts, and the nature of sampling from a rural population.  For 
example, Graves states that patients from a rural population generally have a lack of financial 
resources and health insurance, therefore refusing CVD screening.  As well, patients in rural 
areas are less likely to access preventative treatment and are more likely to delay treatment when 
ill.  Nurses and other healthcare practitioners should assess for risk factors related to CVD, and 
help to deliver health promotion and education surrounding CVD.  This can also be said for AF, 
and similar actions can be taken to encourage better health promotion and education for this 
demographic of patients. 
In looking at studies that present rural populations accessing secondary or tertiary care in 
a larger center, the pilot study by Pesut, Laberge, Sawatzky, Mallinson and Rush (2013), aims to 
“describe the needs and experiences of rural individuals commuting to an urban center for 
percutaneous coronary intervention” (Pesut et al., 2013, p. 88).  This study was chosen for its 
focus on the experience of rural patients accessing care from an urban setting and health 
outcomes after discharge to their homes.  The authors noted that those living in rural areas are at 
higher risk for cardiovascular disease in comparison to urban dwellers, and that twenty to thirty 
percent of Canadians live in rural areas.  Though access to treatment in hospital is good for rural 
patients, barriers to education regarding their medical condition and lifestyle changes are 
prevalent in this population, and serve to be a major influence on health status.  Participants for 
phone interviews were recruited from rural areas, rural being defined as an area with a 
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population less than 10,000 and more than two hours by car away from a treatment center.  The 
“Patient Adherence and Satisfaction Survey” was used for data collection.  All of the participants 
had undergone percutaneous coronary intervention (PCI), and as a follow up were asked a series 
of questions from this survey with Likert-scale questions, in which rural patients were recruited.  
Thematic accounts were constructed from these interviews.  Twenty-five percent of the six-
hundred and twenty-six telephone participants were rural residents.  The findings showed that 
residents in rural setting were 1.5 times more likely (OR 95% CI, 1.0 to 2.3; adjusted for 
differences in age and sex) to experience chest pain at least rarely (forty-four percent) following 
their surgery, versus thirty-four percent of urban residents (Pesut et al., 2013, p. 91).  Of the rural 
residents, forty percent of patients had arranged an appointment with cardiac rehabilitation, 
sixteen percent declined participation, eleven percent had not been referred, and thirty-three 
percent had none available.  The authors did not finding adequate reasoning as to why urban and 
rural residents were similar in cardiac rehabilitation attendance, as rural access is limited.  
Limitations of this study include a relatively small cohort of participants and collection of data 
through a satisfaction survey. 
With a look at rural management of AF, not only does non-adherence to medication 
affect stroke prevention in patients with AF, the underuse of such medication was also found to 
be an issue.  This is explained in the article ‘Adverse outcomes and predictors of underuse of 
antithrombotic therapy in medicare beneficiaries with chronic AF’ authored by Gage, Boechler, 
Doggette, Fortune, Flaker, Rich and Radford (2000) is a comprehensive look using a 
retrospective chart review at different reasons for underuse of antithrombotic medication.  The 
researchers note that antithrombotic therapy is under prescribed in the nonvalvular AF patient 
population, which can lead to serious consequences.  A chart review of Medicare beneficiaries 
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from 1993 to 1996 was undertaken.  The objective of this study had three main aims; “to 
document the use of warfarin and aspirin therapy in Missouri Medicare beneficiaries with 
chronic non-valvular AF; to identify factors associated with warfarin and aspirin underuse; and 
to document the association between prescription of warfarin and aspirin at hospital discharge 
and adverse outcomes in this elderly, frail population” (Gage et al, 2000, p. 822).  Data were 
analyzed using the Cox proportional hazards model to determine the association between 
prescription of warfarin or aspirin with adverse outcomes (Gage et al., 2000, p. 823).  From this, 
the researchers determine relative risk reduction.  Through their analysis of the data, the authors 
found that only fifty-five percent of eligible patients discharged from the hospital were 
prescribed an antithrombotic medication (thirty-four percent warfarin, twenty-one percent 
aspirin).  According to Gage et al. (2000), warfarin sodium provides a reduced risk of ischemic 
stroke by sixty-eight percent and aspirin provides a twenty-five percent risk reduction in the 
same. The findings of this study determined that the underuse of antithrombotic medication 
resulted in adverse health outcomes.  Specifically, in this study’s population, warfarin was 
associated with a thirty-one percent relative risk reduction in the rate of an adverse outcome 
(P<0.001) while aspirin was associated with a nonsignificant eleven percent relative risk 
reduction (P=0.19) (Gage et al., 2000, p. 824).  As well, factors such as advanced age, female 
gender, and rural residency were also shown to be important predictors of anticoagulant use, with 
these populations being significantly less likely to receive AF treatment.  For example, the 
authors state that for females patients discharged from an urban hospital, the odds of receiving 
antithrombotic therapy were 1.5 times lower than that of a male patient.  This number drops 1.7 
times lower in their rural counterparts (Gage et al., 2000).  Though this study provides useful 
information on comparing rural and urban patient populations, this study failed to provide 
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information on whether the patients refused antithrombotic therapy due to personal preference or 
physician prescribing discretion.  At the time of this study, antithrombotic therapy may have 
been less common, therefore, risking reliability of the results. 
In summary of the theme of rural health care (and rural residence) as a factor in AF 
treatment and risk for ischemic stroke, there are several points that can be taken from the 
literature.  One of the major factors is patients’ inability to access health care from tertiary 
centers is the physical distance from their rural community to a larger center, whether that is in 
relation to making the window of time for treatment or the costs involved with travelling (De 
Angelis, Bunker, & Schoo, 2008; McGregor et al., 2005).  In looking at alternative measures for 
an increase in access to diagnostic equipment in rural communities, and point-of-care devices 
such as the CoaguChek S for INR testing (Jackson et al., 2004) could be a possible option for 
increased access to laboratory testing in a timely fashion, increasing patient access to diagnostic 
procedures.  Further research is needed to explore the lived experiences of rural residents to 
better understand how health care providers can optimize medical care. 
Summary 
 Some of the key messages that can be summarized from this literature review are that 
prevention of stroke in patients with AF is crucial to ensuring optimal health outcomes and 
improved quality of life (Awadh et al., 2010).  The most important factor in prevention is 
adherence with antithrombotic therapy. It is of utmost importance that healthcare providers 
screen patients for stroke risk with a tool such as the CHA2DS2VASc and based on results 
provide necessary antithrombotic treatment (Björk et al., 2013; Chao et al., 2012; Framingham 
Heart Study, 2015; Gage et al., 2000; Gattellari et al., 2008; Waterman et al., 2004).  For patients 
living in rural or remote locations, treatment at times is not easily attainable due to physical 
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distance to tertiary or even sometimes primary health care (De Angelis et al., 2008; McGregor et 
al., 2005).  Point of care testing for INR levels, or utilizing direct oral anticoagulants can help 
patients access more effective care in a timely manner to ensure that they are maintaining a 
therapeutic INR or anticoagulation with the appropriate dose of medication (Jackson et al., 
2004).  With further research on understanding and managing risk for stroke, health care 
providers can understand more clearly what is needed to help patients with AF prevent this 
deadly disease. 
 
Gaps in the Literature 
 There were several gaps in the literature.  First of all, there was limited research 
originating from Canada, most of the articles utilized were from either Australia or the USA.  
Secondly, there was a lack of research pertaining to the experience of the patient.  Few articles 
were explored from the patient’s point of view, but rather, from the health care provider or 
researcher’s point of view.  Most of the research focused on specific elements of medical 
management with little context of patient or health service factors.  Many of these studies were 
retrospective analyses or questionnaire studies and did not focus on the experiences or 
perspective of the patient with AF.  By undertaking a qualitative study exploring patient 
experiences and understanding of their management of stroke risk, we as health providers will 
gain valuable insight and respond to these gaps in the literature.  As well, many of the studies 
were undertaken in an urban setting, and as such lend limited data to a rural or remote setting.  
As identified in the study by Kääriäinen et al. (2012), antithrombotic medications are proven to 
be the most effective method of preventing stroke.  By exploring the needs of rural and northern 
residents, researchers can identify strategies that can support self-management. Understanding 
  50
these issues will help to identify patients’ educational needs and in turn will enable the provider 
to support the patient to adhere to their treatment and to optimize their health outcomes.  This is 
particularly important in rural and remote settings where access to specialist services is more 
limited and where patients are required to travel long distances to access care.  In response to this 
gap in knowledge, this research provides a qualitative descriptive study exploring experiences of 
patients’ with AF in areas of northern British Columbia.  The following section will provide an 
overview of the methods used in the study, focusing on a qualitative descriptive design. 
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           Chapter Three 
Methodology 
A qualitative descriptive design was adopted for this study.  This approach was chosen to 
assist me, as the researcher, to understand the experience and insights of the participants and to 
examine phenomena within the natural context (Magivly & Thomas, 2009; Morse, 1991).  As a 
nurse, excellent patient care begins with a thorough assessment to determine the patient’s health 
status and needs.  In the same way, qualitative research can contextualize and uncover patient 
experiences that health care providers may otherwise take for granted in practice by investigating 
the patient from a multifaceted point of view (Morse, 1991).  A qualitative descriptive approach 
was chosen for its ability to allow for a full description of the phenomenon under study, with 
minimal theoretical limitations (Magivly & Thomas, 2009).  Further, it aided me to explore and 
understand the lived experience of participants with AF.  Qualitative description is commonly 
used in nursing research and is considered the “least theoretical” methodology available to 
researchers (Sandelowski, 2010).  However, qualitative description allows for findings that are 
closer to the data results due to less constraint of theory of its methodology, and potentially more 
translatable in the practice setting (Sandelowski, 2010).  This research addressed the question, 
“How do patients in rural northern British Columbia with AF understand and manage their risk 
of stroke?”   
Research Design 
 In health care, understanding the experience of the patient is crucial for the health 
practitioner if they are to provide excellent, patient centered care.  More recently, through 
initiatives across Canada including the Strategy for Patient-Oriented Research (Canadian 
Institutes of Health Research, 2013), researchers across Canada have started a movement to 
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highlight the importance of patient and caregiver perspectives to further inform the development 
and delivery of healthcare interventions (Canadian Institutes of Health Research, 2013).  If we as 
practitioners can help to understand the perspective of the patient, we can improve the quality of 
healthcare offered to promote healthier communities by developing responsive and relevant 
solutions to health issues.  In rural and remote areas, research is warranted to improve health care 
access and experience for northern British Columbians.  In response to these research gaps and 
needs, I undertook a qualitative study to explore the experiences of patients with AF in areas of 
northern British Columbia.  The study focused specifically on understanding and management of 
stroke risk, which will improve and optimize patient care by understanding key barriers and 
developing patient focused care and effective health services.  
Sampling and Recruitment 
 I had initially planned to recruit participants from physicians in a rural town in northern 
British Columbia, and was assured that I would be assisted in gaining contact with physicians by 
one of the administrators at this hospital.  Unfortunately, the hospital was experiencing a 
structural change, causing my research project to fall to the side.  My recruitment was delayed by 
one year, and finally I was assisted in recruitment by a cardiologist in a city in northern British 
Columbia.  With the help of two physicians, I was able to recruit a variety of participants from 
several towns and one city in northern British Columbia.  As a nurse working at a hospital in a 
rural town in northern British Columbia, I was careful to distinguish myself as a student 
researcher rather than my role as a nurse.  During the recruitment stage, I approached several 
medical outpatient clinics and prepared recruitment material for the physicians.  I dropped off a 
package to the physician’s medical office assistant with the following forms: Invitation Letter for 
Study Participant (Appendix I), Participant Information Letter/Consent Form (Appendix J), 
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Physician Recruitment Letter (Appendix K), and Study Interview Questions (Appendix L).  To 
avoid a risk of coercion between myself and the physician, I took care not to directly ask the 
physician for assistance with recruitment, as I have an established nurse-physician relationship in 
practice.  I emailed the MOA of the physicians, to confirm that they had received the package.  
After an agreement from the physician to help with recruitment, the participating physicians 
provided me with a list of participants who were willing to participate in the study that they had 
chosen from their medical practice.  From the cohort in one town, I recruited seven participants 
and five from a larger city, both in northern British Columbia.  I obtained informed consent from 
the participants with the help of the physician explaining the study to their patients and an 
information package which was sent to the participant.  The included consent form was signed 
by the participant and returned via mail to my academic supervisor.  After gaining verbal and 
written consent, I called the participant (contact information was provided to me by the 
physician) and I conducted my interview consisting of eleven questions.  All interviews were 
recorded verbatim with the participant’s consent, and then analyzed thematically using NVIVO 
11.  This analysis was then further discussed with my supervisor, and organized using a 
conceptual diagram with a whiteboard and/or notebook.  One of the clinics in a northern town 
that was asked to assist with recruitment with the study agreed to initially participate, but did not 
follow up with recruitment and eventually did not participate.  This potential data would have 
been a great asset to the data set, and would have given a wonderful insight into AF and stroke 
prevention in northern British Columbia.  As a silver lining to this unfortunate set back in 
recruitment, I was able to recruit participants from three different communities in northern 
British Columbia, which did result in a rich data set with valuable information for this study.    
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The type of sample strategy selected for this study was convenience-criterion sampling.  
Participants were identified from health clinics in one town and one city in northern British 
Columbia.  Participants who met the following criteria were invited to participate: (i) patients 
who have been diagnosed with AF, (ii) patients who live in northern British Columbia.  Initially, 
I intended on recruiting only participants who were over the age of sixty-five.  The physicians 
assisting with recruitment included participants as young as thirty-nine to highlight that AF is a 
widespread issue affecting people under the age of sixty-five.  Therefore, I changed my research 
question from “how do patients over the age of sixty-five living in rural northern British 
Columbia with AF understand and manage their risk of stroke?” to “how do patients living in 
rural northern British Columbia with AF understand and manage their risk of stroke?”.  The 
research question did not change until after the literature review was conducted.  With a 
qualitative design, a large sample size is not necessary, but rather, sample size is determined 
when saturation of data is reached (Loiselle & Profetto-McGrath, 2011; Sandelowski, 2000).  A 
sample of twelve participants was recruited. 
Participants were provided with a comprehensive information sheet and consent form.  
As well, each prospective participant was briefed by their physician on the study before I 
contacted them.  All participants had the opportunity to ask questions or seek further 
information, and informed consent was obtained during the telephone conversation and/or was 
signed and returned to the researchers via mail.   
Data Collection 
The primary method of data collection was in the form of semi-structured interviews.  
Interviews enabled the in-depth examination of the experiences and needs of patients with AF 
and provided the researcher with insights of the participants’ experiences of living with AF.   
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Following informed consent, participants were contacted to arrange an interview.  All 
interviews were undertaken via telephone at the participants’ convenience.  The primary method 
of data collection was in the form of a semi-structured interview that included eleven open ended 
questions (Banner, 2009).  In looking at using “grand tour questions” as developed by Spradley 
(1979), the interviewer can help simulate the experience of the person under study.  Grand tour 
questions are typically an open-ended questions that guide the participant to give a full breadth 
answer as to what their lived experience looks like (Spradley, 1979).  A grand tour question 
allows the researcher rich insight into an experience or phenomenon during the interview.  These 
grand tour questions usually lead the interviewee into a detailed description.  From here, the 
interviewer can ask about specific phenomenon related to the experience, referred to as “mini 
tour” questions (Spradley, 1979).  A practice interview was conducted with my supervisor prior 
to data collection to hone the skills of myself and to test the interview questions.  During the 
interviews, follow up questions were used to prompt the participant where further information 
was sought.  The interviews were tape recorded and transcribed verbatim to preserve accuracy.  
To define the study sample, basic clinical and demographic data, including age, gender, AF 
presentation and complications were collected throughout the interview.  In addition to the 
interview data, the researcher collected basic clinical and demographic information from the 
participants.  If there are any gaps (and with the agreement of the participant), further details 
(such as participants’ ages) were obtained through their family physician.  The interview 
questions were developed to reflect the key focus of the research and were tested before 
interviewing the participants to ensure that they were easy to understand and free of jargon.  
Follow up questions and probes were used to see further information or to gain clarity around the 
patients’ experiences (Rubin & Rubin, 2005). 
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One potential limitation of the questionnaire was the wording of one of the questions, 
“has anything in your life changed since getting diagnosed with atrial fibrillation?  If so, what?”  
For several of the participants, the researcher needed to repeat and/or rephrase the question for 
them as they did not understand it, or they did not know how to answer it at all.  Many chose not 
to answer this particular question.  This was problematic, especially because the methodology 
used was qualitative description.   
 
Data analysis 
Data analysis involved the development of codes and themes to provide a detailed 
description of the experiences of patients with AF in northern British Columbia.  Data analysis 
included transcribing the interviews verbatim and close reading of the transcripts, as well as a 
detailed examination of the data for codes that represent common topics or similar or different 
experiences.  Themes linked these on a more abstract level and captured patterns and processes 
(Sandelowski, 2000) determined from that data, rather than super imposed on them (Streubert & 
Carpenter, 2011).  This was determined through discussion of the data with the researcher and 
supervisor, and the use of a whiteboard to expand on ideas from the data to help with analysis.  
Data analysis software was used as a tool to assist with data analysis.  To help in the coding and 
sorting of data during analysis, NVivo 11 QRS international (QRS International, n.d.) was used.  
This program helped organize thoughts and patterns found within the transcripts, and coding 
determined where there were similarities and differences between interviews.  I found the NVivo 
11 software difficult to use during the coding stages, and felt that the use of conceptual maps and 
peer check in with my supervisor to be the most effective methods of assisting my analysis.  
However, I found that NVivo was useful for storing and organizing the data.  Before that, 
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though, there was an on-going analysis as interviews were collected to ensure that the questions 
made sense, that the participants answered them in a descriptive manner, and that all of the 
information that was needed to answer the research question was collected.  Conceptual maps 
were created during the process of linking the information from the data to observe where the 
data formed themes and subthemes (Appendix M).  It was essential to ensure that not only did 
the researcher collect a variety of data, but also a deep understanding of what the participants’ 
understanding around stroke risk was.  By asking simple questions, the researchers hoped to gain 
a complexity about what the participants understood, and analyze the data to represent their 
voice and organize the data into themes.  Several participants stood out with notable quotes, but 
care was taken to include all participant data from the data set.  All twelve participants in this 
study had invaluable input to this study, and the data was used accordingly to support themes 
found (Rubin & Rubin, 2005). 
Ethical considerations   
When undertaking any form of inquiry, the researcher must consider the ethical 
implications of a given study.  Ethical considerations relevant to this study included interviewing 
participants about their personal healthcare experiences, power relationships and confidentiality.  
Firstly, during the interviews participants were asked to speak about their experience of living 
with the risk of stroke and about their decision making related to the management of this risk, 
such as medication therapy.  As such, this could have caused the participants to become 
emotional about their experiences and may have led to psychological discomfort.  In the event of 
any discomfort or emotional upset, the interview would have been paused and the participant 
would have been asked if they wished to continue.  A list of resources of local counselling 
services was available to all participants if needed.  As it was, all of the participants were willing 
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to discuss their disease process, and share their thoughts in the interview over the telephone 
without any stated issues.  Secondly, there was the potential for imbalanced power relationships.  
Nurses are generally trusted and it is important that the researcher role is fully acknowledged.  
To prevent any power relationship issues, the participants were provided with a comprehensive 
information sheet and were provided with sufficient time to ask questions, seek clarification and 
make a decision.  Participants were informed in these documents that their participation was 
voluntary and that if they chose not to take part, they would not be asked for a reason nor would 
it impact their current care in any way.  As well, I ensured that the participants understood that I 
represented myself as a student researcher as opposed to a health care provider in this role.  
While no adverse situations arose during the interviews, this role clarity was an important part of 
the research process.  Finally, this research was undertaken in both small and larger communities 
in northern British Columbia.  As such, confidentiality and privacy was of central importance.  
Participants were informed that all information from the study is confidential and that they will 
not be identifiable in any data or report.  As I recruited participants from my home community, 
strict confidentiality on my part was essential.  Further, I informed the participants that I will not 
name them as a participant in this study. 
Only my direct supervisory team has access to the anonymized raw data, otherwise, the 
data is stored securely in a password protected file or locked filing cabinet.  Care was taken to 
ensure that chosen quotes were selected to ensure anonymity, given the smaller settings from 
which participants were selected.  If concern arose around potentially recognizable data, the 
researcher agreed to either not use the data in question or check directly with the participant.  In 
all cases where there were recognizable data (such as specific discussions about a health care 
provider), this was not included. 
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The research was undertaken in congruence with the ethical principles of the Tri 
Council’s policy on human participants in research (TCPS 2: CORE) and ethical approval was 
sought from the Research Ethics Board of the University of Northern British Columbia and the 
Northern Health Authority.  Further, I have completed the Tri-Council Policy Statement course 
on research ethics (TCPS 2: CORE) (Panel on Research Ethics, n.d.), to ensure familiarity with 
the ethical principles and expectations around ethical research practice.  I was also confident that 
I could seek guidance from my supervisory team and research ethics board at any time should 
there have been any ethical issues or concerns. 
Rigor 
 In using a qualitative descriptive research approach, there are several ways to ensure that 
the research is undertaken rigorously.  Four major concepts have been identified as providing the 
basis for strong rigor or trustworthiness in qualitative research: credibility, dependability, 
confirmability, and transferability (Schwandt, Lincoln, & Guba, 2007).   
 Credibility is based on a number of factors, including the researchers’ training and 
background related to the research at hand, the researcher’s personal connection to the people or 
topic studied, and prior knowledge brought to the study (Patton, 1999).  My background as a 
health care provider dealing with AF and stroke on a daily basis in my career has prepared me to 
explore the lived experiences of this disease.  As a Registered Nurse working in an acute care 
setting in a rural community, I see the impact that AF has on patients’ lives.  These past 
experiences provided a good introduction to the area of interest, however, I was cognizant of 
these past experiences in the analysis of the data to ensure that I was questioning the data 
appropriately during analysis.  These reflective processes and awareness of one’s own 
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knowledge background was important in ensuring the discovery of credible findings from the 
research.  To achieve this, I used a research diary to document the research process. 
 Dependability in qualitative research is based on the credibility of the findings 
(Schwandt, Lincoln, & Guba, 2007; Streubert & Carpenter, 2011).  Triangulation is the gold 
standard for increasing dependability, which utilizes multiple methods and data sources to 
strengthen the data (Patton, 1999).  Throughout the process of collecting data, transcription, and 
coding, I had prolonged immersion in the data, and was able to analyze the data in ways that 
similarities and differences were identified and explored.  Verification of the transcriptions and 
analysis were confirmed with my supervisor. 
 Confirmability is the ability to confirm the results of research (Schwandt et al., 2007; 
Streubert & Carpenter, 2011).  The data were collected in open ended interviews and recorded 
verbatim, and then analyzed for themes, and are discussed in detail in the findings and discussion 
chapters of this thesis.  Analysis was undertaken in consultation with a supervision team.   
Finally, transferability of this study’s results to the lived experience of people living with 
AF or stroke will be limited to those people who also live in similar geographical areas and share 
similar demographics as the participants in northern British Columbia (Schwandt et al., 2007; 
Streubert & Carpenter, 2011).  As this study focuses on the lived experience of a limited group 
of people living in a combination of rural and urban settings (although with a common disease), 
the results may be transferable to similar populations living with AF or living in rural 
communities, yet may lack generalizability within the traditional sense.  The data and research 
approaches will be presented in detail to aid interpretation of potential transferability. 
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Situating self 
 Situating myself in the research was an important process and played an active role in the 
collection and analysis of the data.  Realizing one’s own presuppositions and previous 
experiences is important in achieving rigorous analysis of the data (Darawsheh, 2014). As a 
Registered Nurse working in a rural northern British Columbian community, I get to see first-
hand the health care access issues my neighbors, family, friends and fellow community members 
live with on a daily basis.  I was born and raised in the community that I currently work in, and 
as such, have a vested interest in better health care access for this area of British Columbia.  I 
have negative biases towards the lack of access to higher levels of health care in rural and remote 
areas.  This is due to my personal experiences working in a healthcare system that does not 
always allow timely treatment for patients needing care from secondary or tertiary health care 
facilities in cities such as Prince George or Vancouver, B.C.  As previously discussed, during the 
interview process, I engaged in a reflexive process in relation to the analysis by establishing 
boundaries between my role as a researcher and a health care provider (Darawsheh, 2014).  I 
achieved this by exploring my presuppositions, beliefs and completing a research diary to 
document analysis and my own perceptions.  I acknowledge that throughout this study, my 
experience as a Registered Nurse grew from that of a new graduate to now a nurse with over five 
years of experience.  With the growth of my knowledge, my perspective changed as well.  As I 
continued to interview more participants, my ease with research and data collection grew.  The 
more experience I gained in practice and in research, the more my knowledge grew about what 
living with AF is like for someone living in northern British Columbia, including their 
understanding and management of their disease to prevent stroke. 
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Knowledge translation 
 I propose to share the findings of this research in several ways.  Firstly, I plan to share the 
findings of this research through a peer reviewed publication in a relevant healthcare journal.  I 
will also present my findings at a conference.  I will create a plain language summary of my 
findings for the participants in this study, as well as for anyone that may be interested in the 
findings.  Finally, I will create a brief research summary for healthcare providers that will be 
distributed via email or relevant websites. 
Summary 
 This qualitative study explores the experience of patients with AF in northern British 
Columbia and seeks to explore their perspective of stroke risk and decision making regarding 
stroke prevention.  There are few studies that have addressed these issues, and even fewer that 
have focused on the rural and remote setting.  Those rural and remote communities are 
particularly vulnerable as they have limited access to healthcare services, including specialist 
services typically used in the management of AF.  As such, these patients are at a greater risk of 
potential complications.  The outcomes of this research could be used to improve the 
management of AF through understanding the perspectives and needs of these vulnerable 
patients with AF.  In conclusion, AF is a significant public health issue as a chronic disease.  AF 
is projected to be on the rise dramatically over the coming decade (Chao et al., 2012).  By 
understanding the lived experience of these patients, we can optimize decision making and 
patient outcomes which may in turn decrease health care cost.  The following section will present 
the findings of my research study.  
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Chapter Four 
Findings 
Twelve participants were enrolled in the study and in-depth semi-structured interviews 
were undertaken and were digitally recorded and transcribed.  I took key phrases and important 
quotes from the interviews that outlined the key concepts relevant to living with AF and the 
understanding and management of stroke risk, and with the software NVIVO 11, I coded and 
analyzed the data into themes and expanded subthemes. Three core themes emerged following an 
in-depth analysis of the interview data, including: living with AF, stroke prevention, and 
navigation.  As well, the unique features of living with a chronic illness in a northern British 
Columbian community were explored.  
Theme One: Living with Atrial Fibrillation 
  One of the main themes that emerged from the analysis of the data was the experience of 
living with AF.  The participants faced varied burdens and impacts as a result of their AF 
symptoms, and many reported that AF affected their lives and quality of life.  For the 
participants, symptoms ranged from mild in nature, with little to no perceived impact on daily 
activities, to severe impacts that were persistent and created significant personal challenges and 
decreased quality of life.  Through the detailed analysis of these experiences, three subthemes 
were developed: symptoms, medication side effects, and lifestyle change.  These will now be 
presented.  
Symptoms. 
The symptoms experienced by the participants were variable and ranged with respect to 
their intensity and impact.  While two participants denied any symptoms whatsoever during the 
course of having AF, the remaining participants experienced severe, often distressing symptoms.  
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The most commonly reported symptom was heart palpitations, a sensation associated with an 
irregular heartbeat.  The term “heart palpitations” are used in these findings interchangeably to 
describe participants who experienced sensations of an irregular pulse and/or tachycardia.  All 
twelve of the participants reported feeling symptomatic in the initial stage of the detection of AF, 
most commonly reporting heart palpatations, as well as a range of other symptoms including 
shortness of breath, fatigue, and/or chest pain.  Table two lists the reported symptoms by each 
participant: 
Table Two: Symptoms Reported by Participants 
 Fatigue Shortness 
of breath 
Chest 
pain 
Heart 
palpitations 
(tachy, 
irregular) 
Dizziness 
or light- 
headed 
Exercise 
intolerance 
Edema No 
symptoms 
P01 X   X X    
P02    X     
P03 X   X     
P04 X X  X  X  X 
P05 X   X   X X 
P06    X X    
P07  X  X X     
P08 X X  X  X   
P09  X       
P10 X X  X   X  
P11 X  X X X    
P12    X     
 
When asked about their initial experience of AF symptoms, nine of the participants 
reported seeking emergency treatment due to the nature and severity of their initial symptoms, 
while three participants received the diagnosis of AF during an annual physical examination with 
their family doctor.  Overall, it was the experiencing of symptoms that played a role in the 
participants’ outlook on their disease and their response to it.   
Symptoms created significant burden for some of the participants and many of these 
identified that they actively sought ways to prevent episodes of symptoms.  During the 
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interviews, those with more severe symptoms described the need to be vigilant about exertion, 
describing that they were careful to avoid activities that may exacerbate or initiate a troublesome 
symptom related to AF, such as heart palpitations or shortness of breath.  For example, one 
participant explained: “just, like I said, not being as recreation-oriented as what I used to be, and, 
just gotta be careful not to overdo it, and so forth” (Participant 08).   
During the interviews, some of the participants explained that their symptoms were often 
unpredictable and that this could be distressing.  For example, Participant 01 reported that it is 
often difficult to predict when his heart rhythm will go from regular to irregular, saying that he 
would be exercising without any issue, and then afterwards during rest, he noticed that his heart 
would start to beat irregularly: 
It can be going good and then go out, I do know that if I have a hard workout, it just 
about even if it doesn’t kick, like kick out right away, usually, either when I’m- get home 
and I have my protein shake and that, I’ll also sit down, and that’s usually when it’ll 
actually kick out.  Either that, or when I’m laying down in bed.  Which to me, makes no 
sense at all. (Participant 01) 
Participant 01 found that this unpredictability with AF was disturbing, as he had 
difficulty determining what activity would cause his heart to fibrillate.  However, he explained 
that he had decided to keep doing the activities that he loves, such as karate, but kept a close eye 
on his heart rate with the use of heart rate monitors and was cautious about the intensity of his 
exercise.  He stated that he had scaled back the intensity of his workouts during martial arts 
practice, and accepted that he can’t push himself physically to the point that he used to. 
Another participant explained how exercise played a part in exacerbating his symptoms 
of AF.  Participant 03 was at the gym between ten and fifteen years prior when he described that 
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“all of a sudden I felt really weak and kind of like a fluttering, butterflies in my chest”.  He 
explained how a paramedic who happened to be at the gym performed a pulse check on him, and 
told him to access emergency care immediately.  This clinic visit led to his initial diagnosis of 
AF.   
As well as the unpredictability of the symptoms of AF, Participant 11 reported that after a 
twenty-year plateau of his symptoms, they are starting to worsen in severity.  “It got to a point 
where I was just losing strength?  In my body.  You know, I would go out and feed him [the 
dog], and every time I would go out to feed I was like, more and more sure, and now I’m down 
with a little bit of chest pain” (Participant 11). 
For those who did not experience any symptoms of AF initially, and were diagnosed by 
their family physician during a routine examination (i.e. pulse check), the presence of comorbid 
conditions was perceived to mask symptoms that were related to AF or drew awareness away 
from their AF.  For example, Participant 12 adamantly declared that he felt no different as a 
result of AF and that his lifestyle had not changed significantly.  However, he did mention that 
having Multiple Sclerosis did make activities of daily living difficult: “MS is slowing me down.  
So, the A Fib never really slowed me down”.  Similarly, another participant found it difficult to 
determine the origin of his symptoms and had initially mistaken the intermittent dizziness he had 
experienced to vertigo rather than AF (Participant 01).  One gentleman in particular doubted the 
fact that he had AF, recalling the time he went into hospital for shortness of breath due to 
previous diagnosed heart failure, and was found to have AF; “I don’t think I’ve got it, but 
apparently I do; I don’t even know that I’ve got it except when I go to the doctor and they fill it 
out on the form that I do” (Participant 09).  One phenomena of AF is the lack of distinct and 
unique symptoms.  As Participant 09 said, “I’ve not had any kind of symptoms that I could say 
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‘oh, it’s that’.  You know”.  This statement provides an example of the sometimes vague 
symptoms that occur in AF and that this can lead to uncertainty for those with the condition.   
 For other participants, their symptoms had become an accepted and normalized part of 
life, rather than a symptom of a potentially life limiting heart condition.  With the confusion as to 
whether their symptoms were part of AF or something else of benign origin, the participants’ 
decision to access care was often delayed or put off.  For Participant 05, accepting adverse 
symptoms as normal led her to delay seeking help and receiving a timely diagnosis of AF.  She 
explained that in December 2015 she had lost energy and “gained quite a bit of fluid”.  She made 
an appointment to see her family physician regarding the worsening of these symptoms, and was 
found to have an irregular heartbeat.  At this point, she was referred to see a cardiologist.  She 
recalls the conversation with the cardiologist about her irregular heartbeat.  She said, “oh, that’s 
normal”, and they said, “no it’s not”, well I said, “well, for me it is!” (Participant 05).  Until her 
meeting with the cardiologist, Participant 05 did not believe that having an irregular heartbeat 
was a sign of an underlying pathology, exposing her to the risk of stroke if left untreated.  At the 
time of this interview, Participant 05 was taking warfarin and receiving close monitoring from 
her physician for other health concerns.  Similarly, Participant 06 was surprised to learn of his 
diagnosis of AF at the relatively young age of thirty-five when he was receiving a routine 
physical exam for the renewal of his pilot’s license:  
I was doing a physical for a pilot’s license, and that’s when it was first detected.  In those 
days, that could, sort of get me out of it…  I don’t know how quickly I went back into it 
[AF], but I assume fairly quickly.  Now they’ve given up trying to get me out of it. 
(Participant 06) 
  68
Several of the participants noted with passion the inconvenience that AF caused them in 
their life, requiring them to drop everything at that moment and drive to the nearest hospital.  
One experience outlining this inconvenience was when Participant 07 explained that he was 
required to leave his sister’s wedding to get electrical cardioversion when he felt himself convert 
into AF: 
I had one episode last… Fall, when I was in Alberta.  The day of my sister’s wedding. 
It was a gong show, but that was, okay, yeah, I went to the hospital in Alberta, and got 
shocked, and got corrected, and nothing, you know, that was it. 
So.  It’s, it’s just a pain in the ass, cause you gotta drop everything and, yeah, you’re 
pretty much out for a day afterwards (Participant 07) 
Speaking with the participant, it was apparent that AF caused him a significant amount of 
distress in his life.  He was required to drive forty-five minutes to the nearest hospital to receive 
electrical cardioversion to return his heart to normal sinus rhythm.  He reported that he was 
vigilant with his pulse, and frequently checked to see if it was still regular.  Along with the 
significant inconvenience outlined, Participant 01 mentioned the cost of travel as factor in 
accessing medical treatment.  In particular, the need to travel from a northern community to 
Vancouver was time-consuming, taking on average twelve hours to drive to Vancouver, 
especially with the unpredictability of getting an appointment.:  
It’s been a bit costly, and, you know, for going like, to Vancouver and that.  You can’t just 
phone and make an appointment with them for like, you know, say, “I’m coming down to 
Vancouver next month so see ya!”.  It’s like, you’re probably lucky if it’s six months. 
(Participant 01)   
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 In summary, the symptoms associated with AF can range in severity, from none at all to 
distressing and life-threatening.  These varied experiences can make it challenging to understand 
the cause of their symptoms and can lead to uncertainty and distress. 
Medication side effects. 
During the interviews, all of the participants talked at length about their medication 
schedule and how it affected them in their day-to-day life.  Unfortunately, most of the 
participants reported unpleasant side effects from taking their life-preserving medications, 
including drugs to control their heart rhythm and to manage their risk of stroke.  This was 
perceived to be a double edged sword in the management of AF; on one hand, the medications 
can provide innumerable benefits and serve as a medical alternative to more invasive treatment.  
On the other hand, they caused negative side effects such as fatigue, bruising and bleeding.   
Participant 01 reported that taking amiodarone had decreased his level of energy.  The 
combination of this medication’s side effects and his experience of AF has made him aware that 
he is not able to exercise as vigorously as he used to, and he is careful to monitor his pulse while 
exercising.  For this participant, the symptom burden and lifestyle limitations included fatigue 
and exercise intolerance.  While describing the negative side effects of taking this medications, 
he stated, “There’s times when I wish I would of never even found out I had it [AF]” (Participant 
01).   
Another participant (Participant 06) reported that he developed an allergy to a medication 
that he had been taking for five or six years to control his heart rate, reporting that the side-
effects were “like having Parkinson’s disease” (Participant 06).  During a road trip through 
British Columbia, he stopped at a hospital in an urban center because, “I [didn’t] know what’s 
wrong, but I think it may [have been] a problem with my heart”.  He reports that the staff reacted 
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quickly and efficiently, and he stayed in hospital for one night.  During that time, the physicians 
determined that he needed a new medication to control his heart rate.  Participant 06 reports that 
he was prescribed a new medication, and by the time that he returned to his home town several 
hours later, he said that he was “paralyzed” from a drug interaction.  His new medication had a 
negative reaction with his warfarin dose and caused it to become “three-times more potent” 
(Participant 06) and increased his INR to 22 (normal, therapeutic range of INR for patients 
taking warfarin is between 2.0 and 3.0 [“CHADS2”, 2014]).  This placed him at risk for a 
hemorrhagic stroke, a devastating complication related to the risk of taking warfarin.  What 
happened, he explained, was that “my blood was leaking out of the blood vessels and leaking out 
of my body cavity” (Participant 06).  This led to Participant 06 leaving work for two months due 
to this health crisis, and after his INR returned to a therapeutic level, he was referred to a 
cardiologist on Vancouver Island.  He has said since that referral, “It’s been awesome!  I haven’t 
had any problem with my heart [since then]” (Participant 06).  Though he has now found the 
right combination of medications, Participant 06 had to unfortunately endure many ups and 
downs during the initial period of determining what would help control his AF. 
Participant 10 reported negative experiences with prescribed medications in the attempt 
to control her AF.  With one medication that was prescribed by a cardiologist, she stated “I took 
that for, oh, a number of months, and that didn’t do anything.  It gave me side effects, like a lot 
of extra coughing” (Participant 10).  With two other medications that were given to her 
intravenously, she reported “at one point, and both times, I flat lined, and so they didn’t do those 
anymore” (Participant 10).  After her descriptions of these negative side effects, she spoke of 
how she treated stroke risk by getting regular blood tests to check her INR and carefully 
monitoring her blood pressure with her doctor to “keep it down [with antihypertensive 
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medication]” (Participant 10).  She explained that she has been consistent with these treatments, 
and said, “I monitor it very carefully” (Participant 10).  She was unhappy with a treatment plan 
from one cardiologist, and proceeded to seek out a second opinion for different options, implying 
adequate insight into her condition.  These negative experiences have shaped how she proceeds 
with monitoring and compliance to treatments to prevent further complications.  Participants’ 
describe varying degrees of severity and types of medication side effects. 
Again, there seems to be a level of uncertainty in patients who are unsure if the negative 
side effects are occurring from the medication that is treating their cardiac dysrhythmia or from 
other mediation they are currently taking.  Participant 02 reported that he also takes 
chemotherapy agents, “Chemo medication, you know, that might have something to do with it. 
Too.  The side effects” (Participant 02).  
Finally, one participant described how they had refused all medications altogether, citing, 
“The one pill they gave me in the hospital here, just, really weird feeling, almost like you kinda 
want to just shake it off, but it’s, it’s hard to explain.  It’s just, the shittiest feeling you’ve ever 
felt” (Participant 07).  This participant found it difficult to cope with the side effects of the 
medications and instead chose to receive electrical cardioversion every time he goes into AF.  He 
reports having received this procedure “ten or twelve times” (Participant 07). 
Though medication plays a vital part in the treatment of AF and the prevention of stroke, 
it is noted from the data that there is the potential for negative side effects, which should be 
assessed for in every patient.   
Lifestyle changes. 
As previously mentioned, many of the participants were careful to avoid activities that 
exacerbated their symptoms.  Likewise, several of the participants reported that as well as 
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changing their activities, they were also forced to change their lifestyle.  For example, some of 
the participants described how they had previously enjoyed the outdoor activities offered in their 
community, such as hunting, hiking, and canoeing, but now felt unable to do these activities.  For 
example, Participant 12 commented, 
I can’t go out jogging or walking, or hiking like it’s stolen a lot of my lifestyle away.  
Because I was an outdoor hunter/fisher guy, and now I can’t because I’ll be the guy that 
falls down the cliff.  I can’t do some stuff. And it sucks, because I still want to, and in my 
head I still can.  And I’m strong enough to, but I can’t. (Participant 12) 
 Due to the severity of their symptoms, or for fear that they may aggravate their 
condition, many reported that they either decreased their level of involvement in their 
recreational pursuits or stopped them altogether.  For example, Participant 08 reported, “We used 
to go hunting, and hiking all the time, and played ball, baseball, played hockey and so forth, and 
I guess you can’t do that anymore”.  Not all of the participants reported giving up their 
recreational pursuits.  In contrast, one avid outdoors person chose to continue canoeing and 
rafting far from any major center, stating “I’m… Two weeks away from civilization.  I have to 
have a $30,000 evacuation helicopter to get me out kind of thing”.  Him and his wife have 
chosen to live their life as normally as possible, admitting “it’s not a problem to dwell on”.   
Participant 06, who is another avid outdoorsman and enjoys hunting, mentioned that he had gone 
into the back-country and was worried about the possibility of a medical emergency:  
I honestly don’t really try and think about it a whole bunch, but I’m definitely aware of it.  
Like last fall I went on a, like a ten day, back country kind of thing, and, and you know I 
was thinking what was my plan if it happens?  But I’m, you know, midway through this 
thing now, how am I gonna, you know, deal with it. (Participant 06) 
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While not in the back country, or rafting down a river, thoughts of “what if?” occurred to 
Participant 06 while he was performing one of his favorite hobbies: collecting rocks.  “Well, I’m 
getting older now, and I don’t want to blow up somewhere.  I don’t want it to go when I’m 
dragging a big shiny rock from a cliff somewhere” (Participant 12). 
A common complaint among participants was the physical limitations that were now 
placed on them due to AF, with many required to either decrease activity or stop it altogether.  
For example, one participant explained how their experience of illness had led to post traumatic 
stress, stating that he is now “retired on disability for the same length of time [twenty years], and 
post-traumatic stress does play into that” (Participant 11).  Activities that were affected included 
hiking, biking and working, with two participants stating a complete lack of exercise tolerance.  
During the interviews, several participants reported that they were required to decrease or give 
up employment due to AF-related disability and their other comorbidities.  For the most part, this 
came about in response to the symptom burden associated with AF, including fatigue, chest pain, 
and exercise intolerance.  Participant 05 commented: 
I just don’t have, the energy, I just get tired fast.  But I haven’t done anything since 
 March or June either.  Like, I was in school and that, right.  Like, just doing work with 
 special needs kids so it wasn’t like a strenuous job or anything.  (Participant 05)   
Similarly, Participant 04 was forced to decrease the amount of work he does on a daily 
basis due to his physical limitations resulting from AF: “Well, biggest concerns, my biggest 
concern is, that yeah, I’m kinda held back, I can’t do as much work as I used to, and walk as, as 
far as probably, that” (Participant 04). 
Overall, AF proved to cause a number of inconveniences and challenges in the lives of 
the participants, with evidence that this chronic illness has changed how they pursued their 
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interests and hobbies.  AF was seen to have far reaching consequences, and adversely impact 
their quality of life.    
Theme Two: Stroke Prevention 
 The second major theme that arose from the analysis of the data was related to the 
participant’s understanding of stroke risk and decision-making around stroke prevention, as well 
as actionable preventative health measures.  These discussions were particularly centred around 
decision-making upon the use of oral anticoagulants to reduce stroke risk.  Overwhelmingly, 
their decision to maintain their lifestyle and level of activity seemed to play an important role in 
this decision-making to start a medication, such as warfarin, as well as their adherence to the 
prescribed regime.  When examining the data on stroke prevention and decision-making, three 
subthemes emerged from the analysis.  These are: understanding AF and stroke, beliefs and 
practices of stroke prevention, and the emotions behind AF.  
Understanding AF and stroke risk. 
 To make an informed decision about medical treatments, a patient should have a holistic 
understanding of their disease process and the risks and benefits of potential medical treatments 
offered by their physician.  During the interviews the participants were asked, “atrial fibrillation 
is linked to a risk of stroke.  What is your understanding of this?”.  Nearly all of the participants 
were able to explain why they were at an increased risk for stroke due to their diagnosis of AF.  
Participant 03 described the formation of a blood clot in the atria of the heart as: 
 I understand it’s kind of like… I guess as your heart, as your heart valves aren’t beating 
 in the way they’re supposed to, you kind of get a little bit of a, like a whirlpool in one of 
 your chambers which kind of creates a blood clot- possibly creates a blood clot, which 
 then, ultimately, creates strokes. (Participant 03) 
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 Participant 03 was referring to the decrease in cardiac output during AF, and how blood 
can pool in the atria, creating a blood clot and causing stroke.  Remarkably, most participants 
were informed of their increased risk for stroke, and like participant 03, had taken an opportunity 
to research the link between AF and stroke.  One participant reported that “I do know that there’s 
a risk of stroke, I think I’m in a low-risk risk group for it, but it is, I know it still is there” 
(Participant 01).  Participant 06 answered with a similar, supporting statement: “Well, my 
understanding is that I’m a higher risk of stroke than, a person who doesn’t have fib…  And 
maybe I have a two percent risk.  I’m almost 70 years old now, so I feel I need to live today”. 
 Participant 06 had previously taken warfarin, which had negatively reacted with his other 
medications.  He reported only taking aspirin at this point for anticoagulation, and was happy 
with how his medications worked. “For me, it’s not something that’s not gonna go away, it’s not 
terrible, I have to take some medication, to govern my heart, and it works very well” (Participant 
06).  Adding to that, he said, “Warfarin isn’t tame, because you’re always getting blood tests, 
have it monitored, but I haven’t taken warfarin for a long time now” (Participant 06).  Through 
trial and error, Participant 06 had dealt with AF and the negative symptoms causing him 
numerous hospitalizations for thirty-four years, and knew how to deal with his heart condition 
with the knowledge he had gained thus far.   
 Participant 10 had a vague answer when explaining the connection between AF and 
stroke, referring mostly to how her doctor was medically treating her comorbidities and 
monitoring her: “they [her family doctor and cardiologist] work to keep my blood pressure 
down, because of the risk of stroke and made sure that I have my INR checked all the time” 
(Participant 10).  Similar to Participant 10, Participant 02 explained his risk of stroke in relation 
to AF as:  
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Well, I guess it could lead to a stroke, but, I’m on the warfarin it will pretty much prevent, 
or, the medication should prevent me from going into atrial fib, and, let’s see, what’s the 
name of that…  Verapamil. (Participant 02) 
In contrast, a few participants seemed to lack knowledge about their condition or related 
management.  One participant in particular did not appear to have a clear understanding about 
her disease and struggled to answer or even provide basic details about her condition or 
management (Participant 04).  Each answer given by the participants provided a good insight 
into what they understood as their disease process, and their unique risk for stroke from AF. 
Their understanding was based upon the education given to them by a healthcare provider for the 
most part and highlighted the importance of patient education for patients with AF.   
Beliefs and practices of stroke prevention. 
One of the important aspects of this research is to investigate an otherwise understudied 
group of participants living with AF, and to explore their decision making with respect to AF, 
and in particular that of prevention of AF-related stroke.  When asked about their understanding 
of their risk of stroke and the associated decision-making, many of the participants felt that there 
rural located and distance from the larger metropolitan centres was an important factor.  For 
example, many participants of this study explained that they lived hundreds of kilometers away 
from hospitals in larger urban centers and that this was an important consideration in their 
decision-making around stroke risk and the use of anticoagulants to prevent stroke.   
 The uptake of stroke prevention strategies, especially that of oral anticoagulant use, was 
varied among the participants.  Ten out of the twelve participants reported using an anticoagulant 
medication, including aspirin, warfarin, or a novel oral anticoagulant.  Interestingly, only one of 
the participants reported using a direct oral anticoagulant agent, the approach that is generally 
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considered best practice and optimal for patient outcomes.  However, when asked about their 
understanding of stroke prevention and uptake of stroke prevention strategies, many of the 
participants were not clear or were uncertain about the decision making process or the concept of 
stroke risk.  One participant (Participant 07) mentioned that his father had experienced negative 
side-effects of taking blood thinner medication, which affected his decision to refuse 
anticoagulation.  Participant 07 expressed a level of anger and frustration regarding his diagnosis 
and management of AF, mentioning that his father also dealt with “heart conditions”.  When he 
was asked about the decision to not start on a blood thinner medication, Participant 07 answered: 
I just kind of read up on all the side effects, on similar stuff like warfarin and all the other 
stuff.  And I decided that, I’d rather just, yeah, just, not take that, and get shocked.  
Rather than, go on all that blood thinner stuff. (Participant 07) 
He denied ever taking aspirin either, stating, “I was told to take aspirin, which I never 
have.  But I’m not sure if I should be doing that”.  He witnessed his father with bruises and welts 
on his skin as a result of taking oral anticoagulant medications, and did not want to have the 
same side effects of taking these medications.  Participant 07 also described that by living on a 
ranch, he was more prone to injury from occupational hazards involving farm maintenance, and 
thus decided not to take an anticoagulant.  Regarding his work, he mentioned, “I’m always 
bumping myself, and hurting myself, so I don’t want to be caught, you know, bleeding out in the 
middle of no-where.  Just because I’m on this stupid medication” (Participant 07). 
Three participants had difficulty recalling any information about the decision-making 
process and reported little knowledge about anticoagulants or stroke risk.  This was evident when 
Participant 02 was asked about the decision to start or not start an anticoagulant, and she replied, 
“what’s an anticoagulant?”.  An explanation of the terminology of “blood thinner” versus 
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“anticoagulant” was provided when Participant 05 asked, “what’s an anti- what is that?” when 
asked about anticoagulant use, despite admitting that she took warfarin daily.  When she was 
asked about the decision to start warfarin, she replied: “well, I had to, because I had a blood 
clot”.  Participant 04 was vague in her understanding of why he used an anticoagulant 
medication when asked about the decision to start taking a blood thinner medication: “Uh, what, 
why, did the doctor put me on the blood thinner?  Probably for my operation, I guess”.   
Only one participant mentioned using rivaroxaban, a medication in the direct oral 
anticoagulant class.  Four participants described that they had refused to take warfarin, due to the 
unpleasant side effects such as increased incidence of bruising and bleeding, alternatively taking 
aspirin or refusing medication altogether.  As one participant stated, “Warfarin isn’t tame, 
because you’re always getting blood tests, have it monitored, but I haven’t taken warfarin for a 
long time now” (Participant 06).   
The emotions behind AF. 
 When thinking about their risk of stroke and about the consequences of their disease, it 
was clear from the analysis that each participant had a different perspective of understanding and 
managing their AF.  In addition to some of the physical aspects of their disease that have been 
explained, the emotions behind AF were also an important aspect of their experience of living 
with AF. For example, many of the participants described expressed fear and uncertainty related 
to the consequences of AF and the impacts that it had on their lives.  For example, Participant 12 
described that he was fearful about having an AF-related stroke and the potential of losing his 
independence and regular activities of daily living.  He commented: 
 I’m not the kind of live in fear all the time kind of guy, but, like, from what the doctor- 
 [Participant 12’s family doctor], said to me, he doesn’t talk a lot about stuff.  But, just the 
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 stroke part of it, you know?  The stagnant blood, in the top of the heart, and the blah blah 
 blah.  He explained it all to me, and yeah, I just don’t want to stroke and, be a noodle 
 sitting there in a chair, steering with a straw, and having people wash me arse for me and 
 stuff like that. (Participant 12) 
Likewise, Participant 12 also related his fear of AF to the unknown of the disease 
progression.  He had described watching his father and mother suffer with poor health, relaying 
that his father had received a quadruple bypass heart surgery at age 55, and his mother was 
morbidly obese and had high blood pressure.  As he was age 53 during this story, he had felt the 
need to quit smoking in the previous year, stating “I’m not getting any younger…  It’s a big 
recipe for disaster if I keep going the way I am” (Participant 12).  Understandably, he expressed 
wanting to maintain his independence, quality of life, and his health.  
Commonly, when asked what their main concern was in regards to AF, participants 
mentioned their fear of stroke.  Participant 01 replied: “for me, I would probably say there’s also 
a risk of stroke/heart attack”.  Participant 11 mentioned that he had concerns related to receiving 
cardioversion and the chance that “my only concern is that [what] if they miss something?  And 
it just carries on to where it [AF] does some damage…  I’m too young to leave this world, and 
I’m too old to stay in it” (Participant 11) 
In addition to fear, one of the participants expressed anger related to their condition. 
Participant 07 stood out as being particularly angry and frustrated at having to deal with their 
disease process, and the accompanying hardships associated with managing his condition.  For 
example, when asked about traveling to access health care, Participant 07 mentioned that he had 
driven from a rural northern British Columbian town to Vancouver, “all the way over there for a 
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five-minute interview”.  Elaborating, he stated “no one really gives a shit, kind of thing” 
(Participant 07).  
A surprising aspect of some of the interviews, was the ambivalence and stoicism that 
some participants had towards their diagnosis of AF and related stroke risk. For example, 
Participant 05 understood that AF was linked to a risk of stroke by saying, “I do realize that, 
but… I don’t know.  I mean, if I get a stroke, I get a stroke, right?  Not much I can do about it”.  
Participant 03 stated that “I honestly don’t really try and think about it a whole bunch, but I’m 
definitely aware of it [AF]”. 
 Similarly, Participant 06 stated that despite experiencing a life-threatening negative side 
effects of the medications he was taking to control AF, he stated that “I can’t consider mine [his 
biggest concerns regarding AF] to be a serious problem in the sense that I live a very normal, 
active life…  And I don’t restrict myself to staying around the centers for the hospitals, kind of 
thing”.  Participant 06 was referring to that in the event of a medical emergency while in pursuit 
of an outdoor recreational activity, he may not be near a hospital.  He explained that he was 
willing to take the risk of possible permanent disability or death. Other participants mentioned 
that they were happy with the care they received from their physician and were happy to leave 
the details of their care up to their physician and cardiologist.  One participant stated: “My 
family doctor’s kind of, assured me that, you know, it’s something that’s fairly common, and it’s 
not gonna, you know, immediately endanger your life.” (Participant 03). When asked about why 
Participant 04 was on his blood thinner medication, he stated, “why did the doctor put me on the 
blood thinner?  Probably for my operation, I guess”, suggesting that he was content to trust his 
family doctor for the details of his plan of care.  Overall, there were varied responses regarding 
the experience of living with AF and contemplating their stroke risk and prognosis.  
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Theme Three: Navigation 
 The research in this study was undertaken with the information collected from 
participants residing in towns that could be considering rural and remote, and one smaller urban 
centre in northern British Columbia. Health care from a tertiary center can be difficult to access 
from these areas.  During the interviews, the participants talked at length about their experiences 
of accessing healthcare and navigating the system and about finding creative ways to access the 
service.  A further analysis of the data led to the development of three explanatory subthemes: 
ease of access, creativity in the face of adversity, and system failure.  These will now be 
presented. 
Ease of access. 
 Though living in a rural and/or remote area of British Columbia can undeniably cause 
challenges to accessing health care services, the majority of the participants in this study felt that 
living in rural towns did not impact them significantly with respect to accessing the care that they 
needed.  For example, Participant 06 reported feeling very satisfied overall with his experience 
accessing health care in variety of settings, stating, “Health services in the Yukon and British 
Columbia, or anywhere I’ve ever been, has just been excellent if I’ve ever needed them”. 
Likewise, Participant 05 mentioned that “all I know is that you get into Vancouver a lot faster 
than someone living in Vancouver area” (in regards to the length time that a patient has to wait to 
see a cardiologist in Vancouver).  Participant 05 was waiting for a follow up appointment with a 
cardiologist in either Prince George or Vancouver, and was certain that a person living in 
northern British Columbia was able to see a specialist doctor faster than if one lived in an urban 
center.  She continued, “they say people who have heart problems, or if you’ve got whatever, 
medical problems and you have to make an appointment in Vancouver, we have a faster chance 
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here.  I don’t know why” (Participant 05).  Contrary to this statement, Participant 01 stated, 
“when you’re from a small northern community, like going down to Vancouver to see [a 
healthcare provider] it’s costly and it’s really time consuming, and if a person has to go for the 
ablation, I don’t even have a date for that yet…  You can’t just phone and make an appointment 
with them for, you know, say in, you know, I’m coming down to Vancouver next month, so ‘see 
ya’- it’s like, you’re probably lucky, if it’s six months” (Participant 01).  Overall, most of the 
participants felt that they were able to access the services that they needed, when they needed 
them. 
Creativity in the face of adversity. 
 While many positive experiences were shared in the interviews, a small number of the 
participants did experience profound challenges when attempting to access health care services 
for AF.  These included the challenges of accessing health in a timely fashion in a system with 
long wait times, and the need for patients to have an advocate.  In the case of Participant 09, a 
creative solution was needed when he was told that he would have to wait a year before he could 
make an appointment to receive an echocardiogram.  While he needed to see his cardiologist 
once or twice per year, he explained it was pointless to see the doctor unless he had an 
echocardiogram, and the valuable information it could provide, first.  Not to be discouraged, he 
described how he made several calls and remarked “why were they sending me to [City A] when 
you can drive to [City B] and get it right away?”  He continued: “So, they have people doing it in 
[City B], but they don’t tell you that in [City A], everybody assumes you’re supposed to get it 
done in [City A].  He continued to state that, “So, I actually phoned [specialist] and told them, or, 
she phoned me about this, I told them, ‘hey, why are you telling people to wait a year when you 
can drive to [City B]?” After this, the participant explained that they provided a request form so 
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that the participant could access the echocardiogram wherever was convenient or most timely. 
Despite his success in navigating the system, he felt that the system was still not adequately 
supporting patients needing access to cardiovascular care in northern BC.  Similarly, this 
participant also explained how he had worked to navigate the system to get convenient access to 
blood work in order to monitor his INR levels due to his warfarin therapy.  He commented that 
he accesses his INR blood work results in an efficient manner by having his blood drawn through 
a privately owned laboratory not associated with the public health care system, which meant he 
could receive his INR levels online and then titrate his own dose of warfarin accordingly.  He 
commented: 
 Well, the other thing that they do, or don’t do, is that, if you go to the hospital, or, the 
 [public health care] approved labs to get your blood work done, there’s no way that you 
 can get the results- you have to go to a private lab, which is fine, and get your own results 
 online, on the my e-health thing, to know about your warfarin, right?  To know what it is.  
 Instead of waiting for the doctor to phone you.  So I go to the private lab; all the 
 specialists hate it, because apparently it’s not on your records, as readily as if you go to 
 [public health care] labs, but all they’d have to do is make you a way that you could 
 access it, and it would be fine. (Participant 09) 
 Noting a benefit of going to the privately owned laboratory versus a public health care 
laboratory, “obviously, you can’t make appointments with [the public health care] lab.  You can 
at [the privately owned laboratory].  So.  I work the system as best I can for me” (Participant 09).  
While this participant displays how the health care system is a difficult and murky place lacking 
transparency at times, he has fortunately found ways to navigate it.  By utilizing the privately 
owned laboratory, and taking onus for the costs involved, this participant has better autonomy 
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over controlling his INR level, and finding creative ways to receive procedures sooner than he 
normally would have (such in the instance of his echocardiogram).  Participant 09 works in 
conjunction with his family MD, providing the results so that his warfarin dose can be adjusted 
accordingly.  In regards to accessing his INR results, Participant 09 mentioned that “all the 
specialists hate it, because apparently it’s not on your records as readily as if you go to [the 
public health care] labs”.  It should be noted that this is an unusual approach to monitoring INR 
levels.  Needless to say, he represents a small group of patients who are able to find ways around 
long waiting times for important procedures, unlike most people in this situation.   
 Similarly, another participant found ways of coping with a sometimes difficult system to 
navigate by rallying advocates to help him in times of health crises.  When asked about whether 
he has experienced challenges in accessing the healthcare system, he stated, “We’ve had a few 
people working on our side, that if we need any assistance or information, they’re readily 
available. To help me out with some of my stuff” (Participant 11).  In addition to that, he 
mentioned the invaluable resource that counselling has been up until this point as one of the most 
helpful services: 
The psychological, the counselling, the support that they provide is… I’ve been in and 
out of counselling for twenty-five years, and up until just this last year, it’s the first time 
that I’ve found somebody that I can talk to… There aren’t enough with the degree of 
requirement, as far as doctors and psychologists and psychiatrists versus the patients.  
The patients are far outnumbered, or, outnumber the doctors.  It’s pretty tough.  When 
you move from town to town, it’s pretty hard to find somebody who’s highly qualified 
for what you’re looking for (Participant 11).  
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Though he described a strong support network of friends and family, it was evident that 
Participant 11 has experienced hardship due to his medical conditions.  After twenty-seven years 
with AF, he reported that from 1991 until 2015 his AF was well controlled and he was able to 
carry on with his activities of daily living.  Unfortunately, in 2015 he started to notice that he 
would experience chest pain every time he would go outside to feed his dog.  He reported living 
with post-traumatic stress disorder, which had been a factor in his retirement on long-term 
disability.  Some of the comorbidities that Participant 11 mentioned included (but may not be 
exhaustive) were a history of stroke, shortness of breath, several heart attacks, septicemia, 
pneumonia, hypertension, alcohol abuse, aortic valve defect, and lower back pain that resulted in 
an accidental opioid overdose resulting in psychosis.  Not only did this conversation highlighted 
the importance of having a patient advocate, and the support system that an individual may need 
to navigate the health care system, but the complexity of living with a chronic, life-limiting 
illness. 
System failure. 
 While positive experiences were common place, some participants explained that they 
felt they had been failed by the healthcare system.  Feeling as if she had been treated too 
conservatively in the initial stages of AF, Participant 10  described her journey with treatment 
options during her initial diagnosis of AF as one that has had long-reaching consequences: 
The one doctor I had seen first, the intern, he was going to send me to Vancouver, to see 
about having an ablation therapy done?  And then, at that point, that doctor switched his 
practice to being in cancer, and then [I] went to a different cardiologist and she 
recommended that I not go, so, I didn’t.  Because I believed what she said, and then, 
shortly after that, it became continual, so it wasn’t just intermittent, fibrillation, and then I 
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went to a different cardiologist, and he sent me to Vancouver to see about having ablation 
therapy, while I was there, I went to, I did actually go to have it, I talked to the doctor 
who was doing me after all that, and he said, “once you’ve been in atrial fibrillation for 
continually for a long a time, it’s very difficult to bring you back to a normal heart 
rhythm”.  Uh, I could’ve had it, but it would have probably take about three different tries 
to do it.  One wouldn’t do it, because we live here, and I would have to go down there, 
and I had been handling my atrial fib at that point, and I was continuous, I had been 
handling it much, much better.  So I wasn’t about to go, go and do that.  I figured I was 
better off.  Handling it the way I was. (Participant 10)   
 She went on to explain that she is now treated with a high dose of Lasix (a diuretic 
medication), suggesting that she lives with congestive heart failure at this point.  A key point to 
note from this conversation was that she was told by one doctor that he would not perform the 
ablation procedure due to her geographical location living in northern British Columbia, and in 
part because she had been handling her AF well with more conservative medical treatments.   
While it is difficult to predict whether or not receiving an ablation would have improved 
Participant 10’s quality of life and prognosis, it was clear that the lack of  continuity of care 
around the decisions around her treatment plan impacted her experience and outcomes.   
 In contrast, another participant decided to plan his own care for the treatment of AF, and 
forego medication altogether.  Mentioned previously, he expressed anger when discussing the 
treatment to his disease, and stroke prevention.  Instead of medication, which affected his life 
adversely with negative symptoms, he said, “I feel that my heart is going out of rhythm, I just go 
straight to the hospital and get it corrected [referring to electrical cardioversion]” (Participant 
07).  He mentioned that, “they tried to put me on medication, which, didn’t really work at all.  
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And they tried to get me to just take pills, and I thought that was bullshit.  So, basically all I do 
when I go into A fib, I just go to the hospital.  And, just tell them to shock me” (Participant 07).  
Participant 07 mentioned one of his biggest concerns of living with AF as “the long term side 
effects of having your body do that [stay in AF for an extended length of time], and getting 
shocked that many times.  I can’t know how good that is for your body, anyways”.  Whether or 
not this is a positive plan of treatment, this participant has definitely decided that this is the right 
way to treat AF for now, but did express his curiosity in the disease process of AF during the 
interview process.  In summary, there are varied pathways to accessing services and different 
experiences with respect to the navigation of the system. These access routes can impact a 
patient’s perception of their condition, as well as their overall satisfaction with the care provided 
to them. 
In conclusion, the twelve participants of this study provided crucial data from semi-
structured interviews, forming the basis of three major themes.  Firstly, living with AF proved to 
be a significant burden on the participants, requiring them to accommodate lifestyle changes in 
relation to their disease treatment and health maintenance.  Stroke prevention and decision 
making of the participants was a complex issue.  The level of understanding of the connection 
between AF and stroke risk varied, as well as that of stroke prevention and oral anticoagulant 
use.  Lastly, the third theme addressed navigating the health care system and access, which 
revealed creativity when accessing diagnostic and treatment options in a timely manner.  All 
twelve participants provided rich descriptions, forming a mosaic of personal stories which 
provided insight into their personal experience of living with AF and stroke risk.  Chapter Five 
will continue with a discussion of the findings in the context of the existing literature, as well as 
implications for practice in relation to current research.  
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Chapter Five 
Discussion 
 This section will discuss the findings of this study.  The purpose of this study was to 
explore the research question: How do patients in rural northern British Columbia with AF 
understand and manage their risk of stroke?  To answer this question, there are several themes 
from the in-depth interviews conducted over the course of this project that need to be explored.  
These have been presented in detail in the previous chapter and will now be discussed with 
respect to the current literature.  As this study explored a question that has never been examined 
before, this creates a challenge as there are no studies that specifically look at stroke risk 
management in AF patients in northern British Columbia, or similar settings.  I will compare the 
findings of this study with the existing literature on the topic of AF and related conditions, and 
will determine the implications of these findings for practice, education and research.   
Overview of the Findings 
Three major themes emerged through the analysis of the twelve in-depth interviews 
conducted as part of this research.  These themes were: living with AF, stroke prevention and 
decision making, and navigation. The analysis of the data revealed that AF patients face many 
challenges with respect to AF and the symptoms they experience.  Knowledge of AF treatment 
and stroke prevention therapies was generally poor.  The findings will now be discussed by 
theme. 
Theme One: Living with Atrial Fibrillation 
 AF presented significant challenges for the participants, both with respect to the 
symptoms they experienced and the impacts on their lifestyle and wellbeing.  Participants 
reported a wide range of symptoms and impacts, with some having few symptoms to others that 
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experienced severe and distressing symptoms (e.g. shortness of breath, chest pain).  For those 
that experienced a high symptom burden, they were forced to restrict their activities of daily 
living, such as exercise and hobbies.  In this study, participant 01 mentioned how the 
unpredictability of his symptoms “played on his mind” and were difficult to prevent.  For 
example, he said that he could take part in a strenuous work out without any issue, and then “get 
home [and sit down] and that’s when it’ll actually kick out.  Either than, or when I’m lying down 
in bed.  Which to me makes no sense at all” (Participant 01).   
Previous studies have identified that patients have experienced impaired quality of life as 
a result of their symptoms of AF, such as the study by Dorian et al. (2000) comparing health-
related quality of life between healthy individuals and those who are living with intermittent AF.  
Using a quality of life survey, the researchers measured variables such as “physical functioning, 
role functioning, social functioning, mental health, vitality, pain and general health perceptions” 
to determine perceived quality of life and severity of impairment from AF (Dorian et al., 2000, p. 
1304).  This study by Dorian et al. (2000) was the first of its kind to measure of quality of life in 
AF patients.  Three groups of participants were selected for comparison: an AF group, a cardiac 
control group, and a healthy control group.  The findings showed that patients living with AF 
experience a statistically significantly lower quality of life compared with the healthy control 
group (sixteen to thirty percent lower QOL scoring compared to control p<0.001), with symptom 
burden playing a large part in this analysis.  Similarly, a follow up randomized-control study 
performed by Dorian et al. (2002) measured quality of life in symptomatic patients with AF at 
zero, three and twelve month intervals using a quality of life questionnaire.  The patients with AF 
were randomized into three groups, with each taking a different antiarrhythmic medication 
(amiodarone, sotalol, and propafenone).  The results of the questionnaires were compared against 
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a healthy control group and a cardiac control group questionnaire answers (Dorian et al, 2000).  
The quality of life questionnaire included the use of SF-36 tool to measure health, the Goldman 
Specific Activity Scale (SAS), the symptom checklist to measure frequency and severity of 
symptoms, the Illness Intrusiveness Rating Scale to measure the degree of life disruption by 
illness, as well as the University of Toronto Atrial Fibrillation Severity Scale to measure 
subjective and objective ratings of AF disease burden (Dorian et al., 2000).  The research showed 
that quality of life improved after treatment with an antiarrhythmic medication, particularly if the 
medication prevented recurrence of AF.  Results from this study were significant in measuring 
quality of life in persons with AF.  Scores of twenty-four percent, twenty-three percent, sixteen 
percent and thirty percent lower than healthy individuals on measures of physical and social 
functioning, mental and general health, respectively (all p < 0.001) (Dorian et al., 2000).  As a 
result of these studies (Dorian et al, 2000; Dorian et al., 2002), it is proven that AF decreases 
quality of life, but can be improved by following an antiarrhythmic treatment in pursuit of 
symptom management in AF.  The findings of this thesis research corroborate these findings, 
since impairment of function was evident during the interviews.  For example, Participant 05 
reported the need to stop working and decreased activity when taking care of her grandchildren 
due to her symptom burden, which related to fatigue and edema in her extremities.  She stated, “I 
just don’t have the energy, I just get tired fast” (Participant 05).  An opportunity exists to further 
examine how AF and symptom burden impacts the health and wellbeing of our patients, and as 
nurses, we could incorporate this into our clinical assessments and educational activities. 
As a factor in the management of symptom burden, obesity and sedentary lifestyle is 
linked to exacerbation of AF (Pathak et al., 2015).  In this thesis research, many of the 
participants explained that they were limited in the types of activities they could engage in due to 
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their disease.  For example, Participant 12 this meant avoiding walking, jogging and hiking and 
mentioning that “it’s stolen a lot of my lifestyle away”.  On the other hand, Participant 01 still 
engaged in exercise, but felt concerned about exacerbation of his symptoms.  These concerns and 
limitations affecting physical exercise is important to consider, as it places patients at risk of 
becoming obese. There has been increasing research identifying the importance of weight loss 
strategies to reduce the burden of AF.  As stated earlier in chapter one, obesity can aggravate AF 
symptoms, increasing the severity of symptoms and cardiac remodeling (Goudis et al., 2015; 
Nalliah et al., 2016).  In a five year, long-term follow up study conducted by Pathak et al. (2015), 
the researchers sought to determine the effect of weight loss and weight fluctuation on rhythm 
control in obese and overweight patients diagnosed with AF.  Under the care of a physician, each 
participant received weight loss counselling to either follow a weight-loss plan independently or 
through a physician-led weight management clinic.  For those who experienced a weight 
fluctuation of more than five percent of their body weight, they could expect a two-fold increase 
in the likelihood of recurrent AF (Pathak et al., 2015).  On the other hand, those who maintained 
a weight loss of ten percent of more of their body weight could expect a six-fold improvement 
from AF symptoms.  This study demonstrates the importance of weight loss as a strategy in the 
treatment of AF in patients who are overweight or obese (Pathak et al. 2015).  
Having a proactive approach to risk factor modification may be an important way to 
enhance patient outcomes.  While participants in this thesis research did not explicitly discuss 
obesity and weight control, including further weight management and exercise programs, such as 
those offered through cardiac rehabilitation, may be an important way to improve the outcomes. 
Drawing upon the existing resources within rural communities to support physical activity, as 
well as providing education to healthcare providers that care for patients with AF, could be an 
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important strategy.  Similar to dealing with the symptoms of AF, finding the right medication 
with the least amount of negative side effects was challenging for these participants. 
Managing symptoms can be difficult with the complexity of finding the correct 
medications and limiting activity that can exacerbate or trigger AF.  Participants reported varying 
negative side effects as a result of their medication regime. In particular,  Participant 10 reported 
experiencing a cardiac arrest as a result of an initial dose of antiarrhythmia medication.  One of 
the most widely prescribed antiarrhythmia medication for tachyarrhythmias is amiodarone (Park 
and Kim, 2014).  In Park and Kim’s (2014) retrospective study (n=930) after 2.7 years, 16.6% of 
patients taking amiodarone experienced adverse effects, leading to 15.1% discontinuing the drug 
for the same reason.  Along with negative drug side-effects, health risks associated with this 
medication include pulmonary toxicity, hypothyroidism, bradycardia, prolonged QT intervals, 
ocular changes, asymptomatic elevation of liver enzyme, neurologic dysfunction, 
photosensitivity, skin discoloration, and gastroenterological disturbance (Park and Kim, 2014).  
Another, newer antiarrhytmic drug dronedarone, is mentioned as an alternative.  Dronedarone 
was shown to have less potency than amiodarone, and increased mortality in patients with heart 
failure and permanent AF (Park and Kim, 2014) but proved to have less negative side-effects and 
a lower rate of discontinuation (Park and Kim, 2014).  Regardless of the choice of antiarrhythmia 
medication, long-term monitoring and patient education is required.  This finding is supported by 
the longitudinal, retrospective population-based study by Rankin et al. (2016) that found poor 
adherence to monitoring guidelines in relation to long-term amiodarone treatment.  Toxicity of 
the thyroid, liver, and lungs were the most common adverse drug reaction with amiodarone.  
However, even with these potential negative side-effects, medication to control rate or rhythm is 
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an important aspect of AF management in most patients suffering from AF, and all efforts to find 
the correct medication should be exerted.    
Similar issues have been found with respect to anticoagulation therapy.  Poor tolerance 
for side effects, in addition to high burden associated with medication monitoring may deter 
patients from initiating or maintaining their medication regimes for AF.  Despite newer therapies 
that offer more convenience and less requirement for monitoring, adherence issues continue to be 
identified.  Shore et al. (2015) identified practices that may increase adherence to dabigatran in a 
mixed-methods study (using retrospective quantitative and cross-sectional qualitative data).  The 
researchers introduced strategies to increase dabigatran adherence among patients at sixty-seven 
different sites by means of pharmacist-interventions.  This included chart analyses to determine 
patients’ levels of adherence to other medications and rule out contraindications, provide 
education prior to a patient’s initial dose of dabigatran regarding adverse side-effects, proper 
dosages and storage of medication, and medication adherence monitoring.  Adverse event and 
adherence monitoring by pharmacists led to improved dabigatran adherence, along with longer 
follow up duration.  The researchers emphasized the importance of selecting specific patients for 
monitoring.  Poor medication adherence is also an on-going issue with warfarin (Mayet, 2015).  
Mayet (2015) conducted a cross-sectional survey in an outpatient clinic in Saudi Arabia over six 
weeks with a total of one hundred and ninety-two subjects.  The researcher found that 46.3% of 
respondents had high adherence with their warfarin, and a further 35.4% in a therapeutic INR 
range.  Further studies need to be undertaken to determine predicting factors of adherence and 
good anticoagulation control (Mayet, 2015). 
When analysing the data, it was apparent that many of the participants had knowledge 
gaps with respect to their condition and treatment.  Improving awareness and knowledge among 
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AF patients may provide an important opportunity to support improved patient outcomes, as well 
as greater medication adherence. For example, Tan, Hassali, Neoh and Saleem (2017) undertook 
a qualitative descriptive study by conducting semi-structured interviews with seventeen 
participants.  They identified that medication adherence can be improved by providing patients 
with education about how their medication works and disease pathophysiology by facilitating 
health education talks and screening programs in the community.  Community engagement is an 
important aspect of rural life, and could provide an important strategy for reaching out to patients 
with chronic illness (Tan et al., 2017).  
  AF is a chronic condition that has a dramatic impact on people’s lives, and it is helpful 
to understand AF from a chronic disease perspective.  One framework that can be helpful when 
thinking about living with a chronic illness was developed by Bury (1982).  Bury describes 
chronic illness as a disruptive experience. Through this work on rheumatoid arthritis, Bury 
discovered four major themes that explain the impacts of chronic illness.  These findings can be 
generalized to other chronic illnesses.  He analyzed the responses of thirty patients who 
undertook semi-structured interviews to examine their experience of living with rheumatoid 
arthritis. Bury determined that “chronic illness [is] a disruptive event”, affecting everyday life 
and making the illness the focal point to patients’ lives.  Secondly, Bury described the “onset and 
problem of recognition” as a way to understand the diagnosis of a chronic illness, and how 
patients experienced the initial symptoms.  Many times mistaking their symptoms for an acute 
illness, the participants (particularly the younger participants in their forties and fifties) were 
devastated with receiving a diagnosis that was typically reserved for elderly people.  “Emerging 
disability and the problem of uncertainty” describes both the fear and relief of a diagnosis, and 
the uncertainty of disease progression or effectiveness of a treatment.  Patients generally need to 
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come to terms with the fact that there are sometimes no answers for the cause or effect of a 
chronic illness, and they need to learn to adapt to a new way of living.  Lastly, “chronic illness 
and the mobilisation of resources” refers to the sufferers of chronic illness and their decrease in 
social and community involvement due to their symptoms.  This leads to social isolation, a major 
feature of chronic illness (Bury, 1982).  The author also describes how work arrangements need 
to change to accommodate the person, and how that may strain work relationships to the point 
that the patient leaves employment.  This article concisely explains the hardship and uncertainty 
experienced by people living with chronic illness, and how by understanding the experience of 
chronic illnesses, such as AF, we can better help in promoting a better quality of life and level of 
health (Bury, 1982). 
Along with the challenges of finding the right medication and dealing with symptoms, 
AF impacted the participants’ activities of daily living.  These impacts included limiting physical 
activity, the inconvenience of dropping everything to access emergency treatment when their 
heart rhythm converted to AF, as well as the burden of travelling across the province to see a 
cardiologist.  In terms of lifestyle, participants noted how they had to decrease, or stop certain 
activities (such as outdoor pursuits, employment, and exercise) altogether for fear of their 
condition worsening.  Overall, the participants shared their stories of resiliency in the face of a 
chronic illness, and had found ways to modify their lifestyles in conjunction with the 
inconveniences of AF.   
 
Theme Two: Stroke Prevention 
 Preventing stroke is a key aspect of the treatment plan for patients with AF.  
Overwhelmingly, the participants in this study reported that the decision to start anticoagulation 
was largely based on how the medication would impact their lifestyle.  Stroke risk is an ongoing 
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concern for patients diagnosed with AF, and most patients are required to take an anticoagulant 
medication, such as warfarin or a DOAC, for the entirety of their life (Assiri et al., 2013). 
Though anticoagulants provide a sixty-eight percent relative risk reduction of stroke, these 
medications are not benign and can give rise to significant, and sometime life threatening, side 
effects (Man-Son-Hing et al., 1999).  As a result of this, there are a number of tools that can help 
support patients decision-making around anticoagulation.  In a randomized control trial, Man-
Son-Hing et al. (1999) measured how using a decisional aid impacted decision-making in 
subjects chosen from the SPAF III aspirin study.  The intervention (decisional aid) was a twenty-
nine page booklet, worksheet, and an audiotape that guided the participants through the booklet 
and worksheet (Han-Son-Hing, 1999).  This booklet contained information on warfarin and the 
monitoring required to take warfarin, stroke, and the probability of stroke and bleeding events 
while taking warfarin versus aspirin (Han-Son-Hing, 1999).  The control group received usual 
care in regards to anticoagulation.  The results of the study showed that more people from the 
interventional group were able to make a definite choice regarding anticoagulant medications 
and were more knowledgeable over all about their risk of stroke and bleeding events, when 
compared with the control group receiving usual care (Han-Son-Hing, 1999).  There was no 
significant differences in the decision to start an anticoagulant between the control and 
intervention group.  
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Figure 2, Image 2.  A Patient Decision Aid Regarding Antithrombotic Therapy for Stroke 
Prevention in Atrial Fibrillation: A Randomized Controlled Trial (Ho-Son-Hing, 1999, pg. 738). 
Retrieved from: https://jamanetwork.com/journals/jama/fullarticle/191331 
In this thesis study, seven of the participants reported taking an anticoagulant.  Of these, 
four participants reported taking only aspirin and two did not take an anticoagulant.  With such 
an important aspect of stroke, knowledge about prevention strategies among this study 
population were poor and many of the participants did not recall having a conversation about 
stroke prevention or their specific decision making.  Ideally, all patients who are able to take an 
anticoagulant should do so, and according to the CHA2DS2-VASc guidelines (Appendix B) all 
patients diagnosed with AF qualify for anticoagulation.  In this study, the main reason that 
participants refused anticoagulation was their fear of bleeding.  Emotionally, the participants 
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expressed fear surrounding their diagnosis of AF and the unknown future of their health.  For 
example, after twenty years of successfully maintaining his health after his initial diagnosis, 
Participant 12 reported a recent deterioration in his AF. He found this to be distressing and had 
attributed this deterioration to post-traumatic stress disorder and depression as well as fear.  A 
small number of participants seem ambivalent or accepting of the risks associated with their 
condition.  For example, Participant 05 ambivalently noted “if I get a stroke, I get a stroke, right? 
Not much I can do about it”.  As far us understanding the link between AF and stroke, most of 
the participants were able to understand this link.  However, many of the participants rejected the 
significance between oral anticoagulants and decreased stroke risk stratification, or believed that 
aspirin would be a sufficient alternative to uptake of anticoagulation.  The minority that appeared 
to have more significant awareness of the risk of stroke and AF reported gathering this 
information from education delivered by their healthcare provider, as well as personal research 
using the internet.  Overall, this study has highlighted that there are knowledge gaps, particularly 
with respect to stroke prevention.  People with AF need to receive sufficient education regarding 
preventative and therapeutic treatments in regards to AF and stroke in order to actively 
contribute to their care and wellbeing (Alonso-Coello et al., 2015).  The development and 
implementation of responsive health education programs for patients with AF would assist in 
addressing these knowledge gaps. 
 Overall, there was a lack of knowledge around the purpose and importance of 
anticoagulation therapy among the study participants.  
Medication adherence can be challenging across a broad range of chronic and acute 
conditions.  In the article by Raparelli et al. (2017), the researchers conducted a review of the 
current literature pertaining to factors relating to the adherence of anticoagulants (both vitamin-K 
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antagonists and novel oral anticoagulants) in patients with atrial fibrillation.  DOACs are found 
to be safer and more effective than warfarin, which may increase adherence by patients and 
prescription by physicians following the current guidelines (Raparelli et al., 2017).  The 
researchers related the factors that affect adherence of warfarin to adherence of DOACs in this 
study (Raparelli, et al, 2017).  Poor adherence is a problem in one-third of patients taking 
warfarin, which can lead to an increased risk for stroke and bleeding events.  Nonadherence is 
more prevalent in younger patients, those of lower social-economic status, and those with less 
education regarding their disease and medications (Raparelli et al., 2017).  Comorbidities such as 
cognitive impairment as well as polypharmacy are other factors affecting successful uptake of 
oral anticoagulants, and forty to fifty percent of patient with nonvalvular atrial fibrillation 
(NVAF) do not start a vitamin-K antagonist (VKA) due to fear of fatal complications (Raparelli 
et al., 2017).  They found that there are several factors relating to uptake of these medications, 
particularly DOACs.  These factors include patient preference, physician’s prescribing habits, 
and healthcare system infrastructure and support (Raparelli et al., 2017).  Patients tend to choose 
DOACs over VKA for their fixed dosing and because they do not require regular laboratory 
testing (Raparelli et al., 2017).  Physician under prescribe this class of medication due to their 
overestimate of bleeding risk in patients, as well as the presence of contraindications (Raparelli 
et al., 2017).  Strategies mentioned for increasing adherence in patient with NVAF included 
regularly scheduled contact with healthcare professionals, and attending AF-expert programs 
lead by an interdisciplinary team (e.g. pharmacists, physicians, nurses).   
Another study that investigates adherence is the article by Davey (2012), the author 
outlines strategies for oncology nurses to increase adherence of oral chemotherapy agents in 
patients receiving treatment for gastrointestinal cancers.  The author explores why only fifty 
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percent of patients were one hundred percent adherent with their medication in her data.  Some 
of the factors related to nonadherence of medication included negative side-effects, 
asymptomatic diseases, cost of medication, and lack of knowledge (Davey, 2012).  These issues 
are important to understand, and provide an opportunity to explore ways in which to improve the 
delivery of preventative health services.  Suggestions for strategies to improve patient adherence 
to their treatments included increased education about treatments, discussion of how lifestyle 
factors affect treatment efficacy (e.g. diet, drug-drug interactions) and planning patient follow up 
visits or phone calls with their health care provider to decide on management strategies for 
adverse effects, if any (Davey, 2012).  Likewise, Tan et al. (2017) explained why patients refuse 
to adhere to their prescribed medication schedule.  This study specified investigated why 
patients’ adherence with antihypertensive medications was low.  Several reasons were 
mentioned, included negative side-effects from the medication, low knowledge levels of how the 
medication worked, and  misunderstanding of target blood pressure levels (Tan et al., 2017).  
Suggestions to increase medication adherence included increasing education around appropriate 
medication adherence, as well as explaining the potential negative side-effects and disease 
pathophysiology (Tan et al., 2017). 
 Overall, participants of this study lacked sufficient knowledge about their stroke risk, and 
the significance that oral anticoagulation plays in decreasing their risk for stroke.  In the context 
of this research, education to address stroke risk and anticoagulation therapy would complement 
existing care in the rural setting.  Participants mentioned concerns regarding complications of 
AF, but were unable to articulate their decision-making process regarding stroke prevention.  As 
there are no specialty services such as an AF clinic, education strategies can be implemented 
within primary care clinics or delivered virtually online.  As mentioned, existing tools can assist 
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with patient decision-making and could be implemented within an educational programs 
targeting rural patients with AF. 
 
Theme Three: Navigation 
Living in rural areas can present unique challenges in accessing healthcare compared to 
larger, urban centers (McGregor et al., 2005; Wong and Regan, 2008).  In this study, participants 
expressed their challenges around accessing appropriate healthcare services in a timely manner, 
with some participants indicating that they were often required to travel long distances to access 
the services they needed.  The challenges around access to healthcare in rural communities have 
been widely documented.   
Wong and Regan (2008) conducted a descriptive qualitative study to investigate rural 
residency on the impact of accessibility to primary health care from the patients’ perspective.  
Each participant in this study had an average of two chronic health conditions, which are a key 
driver of healthcare service usage in Canada (Wong and Regan, 2008).  Fifty participants 
completed a questionnaire, and from the results three themes related to primary health care in 
rural areas of British Columbia emerged: 1. Making trade-offs, 2. Continuity of care, and 3. 
Efficiency (Wong and Regan, 2008).  Participants described the difficulty travelling to and from 
larger urban centers to access healthcare, and even the complete inability to travel due to 
finances, weather conditions, and fear of their medical condition worsening during the trip.  
Continuity of care was described as the relationship between the health care provider and patient, 
the information taken from past events and circumstances to make good clinical decisions, and 
patients being able to obtain consistent access and care for their health condition (Wong and 
Regan, 2008).  Living in underserved or remote areas affect all aspects of continuity of care 
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(Wong and Regan, 2008).  Lastly, efficiency across the health system was described as poor, 
with lack of local health care providers and the need to travel for appointments and tests.  This 
study outlined the inequality in healthcare access in rural areas of British Columbia and Canada.  
Suggestions from this study included providing subsidized travel for rural residents, and 
implementing group medical visits delivered by an interdisciplinary team.  In these visits, a 
group of patients with a common diagnosis are provided with education and treatment for their 
condition.  This model of care delivery has been implemented in several rural British Columbia 
communities (Wong and Regan, 2008).   
Likewise, in a review by Brundisini et al. (2013), the authors identified three themes 
explaining rural and remote patients’ experiences in the disparity of accessing healthcare in an 
urban centre.  The three themes were geographical distance, limited availability of trained health 
care professionals in rural areas, and experiencing vulnerability in urban health care settings.  
These issues contribute to overall poorer health in rural and remote residents, and increase 
unwillingness to access health care.   
As mentioned by the participants in this thesis research, travel to see a cardiologist can be 
costly (Participant 05) and inconvenient due to the unpredictability of available appointments to 
see specialist doctors (Participant 01).  However, the participants showed an amazing resilience 
in the face of adversity by finding creative solutions to their healthcare dilemmas.  Instead of 
succumbing to the barriers to booking an echocardiogram appointment, Participant 09 explained 
how he was able to bypass wait times by simply asking to get referred to another community’s 
hospital for an echocardiogram, effectively getting an appointment a year sooner than if he had 
waited for an appointment in his home city.  By getting his echocardiogram in a timely manner, 
he was able to have his regular follow up visit with his cardiologist with his test results in hand.   
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For some participants, the only way to access specialty treatment was to leave their home 
community. For example, during the initial stages of her diagnosis of AF, Participant 10 had 
been advised by a cardiologist that a cardiac ablation would not be in her best interest, and rather 
to continue with a more conservative approach with medications to control her AF.  Another 
factor in this decision was Participant 10 living in a northern city in British Columbia, 
complicating her access (geographically) to the ablation procedure.   
However, Participant 05 believed that by living in a northern British Columbian 
community, northern residents were able to access medical appointments in cities faster than 
those living in urban areas.  There could be a variety of factors at play here, including the family 
doctor’s connection with other cardiologists, the severity of the patient in question’s symptoms 
and disease progression, and whether or not the patient had been seen by a cardiologist 
previously.  After consultation with another cardiologist, she was told that her disease was too 
far progressed to benefit from an ablation, but she might have had a successful procedure 
initially.   
In contrast to participants who were eager to access healthcare, Participant 07 had chosen 
to ignore his doctor’s recommendations altogether, instead electing to seek out electrical 
cardioversion each time his heart rhythm switched to AF.  Reporting poor side effects and 
efficacy from the medications prescribed to him to control his AF, he said that he has been 
shocked “many times”.  While this strategy seemed to work for the patient, there are inherent 
risks with this approach and it was unclear if he had considered these when choosing to seek care 
in this way. For example, electrical cardioversion as the means of treating AF has limited 
efficacy in the long-term.  In a study by Alcaraz et al. (2011) electrical cardioversion is highly 
effective at reversing AF in seventy-five to ninety-five percent of patients during an acute event, 
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but unfortunately has a high AF recurrence rate in the first two weeks afterwards.  Therefore, AF 
management typically involves a multi-prong approach to managing risks and symptoms and 
promoting stability.   
Overall, participants of this study found creative ways to navigate the health care system 
and were often accepting of some of the barriers to access (e.g. travelling to urban centers, wait 
times for procedures).  Most of the participants of this study were very positive about living in a 
rural community and felt satisfied with the care that they receive.   
 
Unexpected Findings 
 When interviewing participants, I had anticipated some of the concerns based on my 
existing knowledge and experience of working and living within a rural community.  However, 
there were a number of findings that I hadn’t anticipated and were novel and interesting.  First, 
there was a number of participants who had taken their plan of care into their own hands and 
create a ‘custom built’ treatment plan of their own, picking and choosing what they wanted to do 
based on their own research and experience.  In particular, Participant 07 stood out to me as the 
most independent, and somewhat rebellious, when speaking to his experience of AF and the 
associated decision-making.  With a combination of negative experiences with health care 
providers (i.e. driving to Vancouver for a five-minute appointment with a cardiologist that told 
him he was doing fine, as well as experiencing negative side effects from the medications 
prescribed to him), he had decided that “getting shocked” was his best option to control AF.  The 
strong influence of patient perspectives puts a strong emphasis upon the need for patients to be 
sufficiently educated about the risks and benefits of all treatments, so that they can make the best 
decision for themselves.  
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 Second, the participants attributed a high level of importance to their hobbies and outdoor 
pursuits, to the point that this was critical in their decision-making around their AF and stroke 
risk management.   When interviewing the participants, it was evident that outdoor activities 
such as hiking, hunting, fishing, and other typically northern British Columbian outdoor pursuits 
were an important factor in the decision to pursue preventative measures against stroke, namely 
that of oral anticoagulant  use.  One participant in particular noted that during a kayaking trip, he 
would need a “thirty thousand dollar evacuation helicopter to get me out” (Participant 06) in the 
event that he experienced a medical emergency, but also noted that when asked if anything in his 
life had changed since getting diagnosed with AF said, “I make a more subconscious effort to 
enjoy the moment.  Enjoy life”.   There is very little available research on the linkages between 
how lifestyle pursuits may impact treatment decision-making for patients with heart conditions, 
and further research on this topic would prove valuable on determining how these factors affect 
patient decision-making in the clinical aspect.   
In summary, this chapter has outlined the findings from three themes: living with AF, 
stroke prevention and decision-making, and navigation.  Overall, throughout this study, it was 
evident that the presence of AF decreases quality of life of those it affects (Dorian et al., 2000). 
The participants experienced a varying range of symptoms, with some reporting that the 
symptom burden they experienced forced them to change their lifestyle.  A proactive approach to 
risk factor modification is recommended with an exercise program to control weight, as well as 
adherence to antiarrhythmic and anticoagulant medication (Park and Kim, 2014; Pathak et al., 
2015).  Poor adherence to anticoagulants is linked to an increased risk for stroke and adverse 
bleeding events (Mayet, 2015; Raparelli et al., 2017).  A knowledge gap between AF and 
decision-making around stroke prevention was evident in this study.  Providing a targeted 
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education program in regards to how prescribed medication works and the pathophysiology of 
AF and stroke could improve patient outcomes (Tan et al., 2017).  Navigation of the health care 
system was investigated in regards to rural residence.  Rural residents experience unique 
challenges in accessing healthcare (McGregor et al., 2005; Wong and Regan, 2008).  Patients 
may have to travel long distances to access primary healthcare, at a personal burden (Wong and 
Regan, 2008).  As a result, these issues of access contribute to poor health outcomes for patients 
with AF living in rural areas (Wong and Regan, 2008).  The implications for future research and 
practice will now be presented. 
 
Implications for Future Research and Practice 
 This research has reinforced the significant burden that AF has upon a person’s life.  As a 
major risk factor for ischemic stroke, understanding the level of knowledge held by the 
participants of increased stroke risk due to AF, as well as their decision-making around starting 
anticoagulant medication was a priority in the study.  Participants’ in this study had poor overall 
knowledge of the benefits of anticoagulant medication, and how important of a role that it plays 
in the prevention of stroke.  Navigation of the healthcare system was a contentious issue for 
some participants, eliciting anger at times when recounting the frustration of the necessity of 
travelling hundreds of kilometres for several minutes of time with a cardiologist.  On the other 
hand, creative solutions were found when problems of access to procedures arose, and an overall 
resiliency was displayed from the participants of this study.  This study addresses a gap in 
knowledge and provides a greater understanding of the experience of living with AF in a rural 
community. However, further research is needed to fully understand this issue and to support the 
development of responsive approaches to patient education and management. 
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 First, further research is needed to address the topic of AF and stroke management in 
rural communities more broadly.  Undertaking further research that extends beyond patients 
living in northern British Columbia and undertaking population level studies that compare rural 
and urban outcomes would be valuable.  This may also include further qualitative research that 
may address lifestyle impacts related to AF and anticoagulation decision-making, as well as the 
study of populations that may face barriers to engagement and for whom may not be well 
represented in the existing literature, such as Indigenous peoples.  Second, another area of 
inquiry that would provide useful data would be the exploration of patients that had experienced 
adverse events related to AF or their treatment (e.g. AF-related stroke).  This would provide 
more information about patient populations that experience adverse outcomes and may also help 
to identify further needs.  Undertaking this focused work would help to further understand AF 
and the associated side effects, as well as gaps in knowledge that may be addressed by education. 
In addition to patient studies, further studies that examine treatment decision-making by 
healthcare provider would provide vital insights and may assist in finding solutions to improve 
the uptake of AF treatment. 
 Third, addressing knowledge deficits on a wider scale would be a valuable strategy to 
raise awareness of AF.  For example, the eleventh and final question that was asked of each 
participant in this study was, “what do you think other people should know about this 
condition?”.  Overall, the most common answer to this question included providing the general 
public with more information regarding the warning signs of AF, and the importance of seeking 
medical assessment and treatment early in the disease process.  One participant suggested a 
campaign similar to that of the Heart and Stroke Foundation of Canada’s acronym for stroke 
symptoms, FAST, which stands for Face, Arms, Speech and Time and refers to four of the most 
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common initial symptoms experienced by those having a stroke (Heart and Stroke Foundation of 
Canada, 2017).  This successful campaign was highly visible in the form of billboards in public 
areas, on the sides of city buses, and the Heart and Stroke Foundation of Canada’s website where 
information about stroke symptoms and treatment are readily available.  A campaign similar to 
the education campaign from the American Heart Association’s information posters (see Figure 
2, image 2) would provide wide spread information to more people.  As seen by Young et al. 
(2018), mass media health campaigns have provided valuable information to the general public, 
with findings that individuals have a high recall of the information presented in these campaigns.  
Historically, these campaigns have helped to foster a change in attitudes and beliefs about a 
certain topic, and increased the overall understanding of a public health concern (such as the 
harms of smoking) (Young et al., 2018).  Undertaking a study to examine the impact of such 
health education programs would be valuable. 
 
Figure 3.  Image 3: AFib Awareness Infographic Poster.   
Retrieved from:http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AFib-
Education_UCM_487898_SubHomePage.jsp 
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The findings of this study suggest that more work needs to be done in educating people 
and raising awareness about the link between AF and stroke risk.  As the most common 
tachyarrythmia, and as the most common risk factor for stroke, AF should be considered for a 
major education campaign.  Specifically, education should be given on the initial signs and 
symptoms of AF, so that the general population can recognize if they themselves or a friend or 
family member have a new onset of AF.  Treating AF as soon as possible can lead to better 
outcomes, and hopefully decrease the risk for stroke as a consequence of untreated AF.  As well, 
educational campaigns should aim to target primary care providers.  Knowledge of evidence-
informed AF management and supporting learning and decision-making with patients is key to 
successful treatment (Cohen & Naccarelli, 2008).  While participants did mention that they were 
happy to leave the details of their health care up to their physician, many of the participants were 
actively engaged in navigating their access to healthcare services and decision-making around 
AF management.  Thus, it is important that patients are sufficiently informed and supported in 
order to take initiative with their care so that they can join the discussion and add to the narrative 
of decisions that could potentially alter their life.  By empowering patients with knowledge 
surrounding their disease and preventative treatments, more people could potentially get on 
board with the latest treatments and hopefully decrease the number of strokes related to AF.  
 Finally, an exploration of specific educational interventions that target oral anticoagulants 
therapy is of the upmost importance.  For example, of the twelve interviewed participants in this 
study, three participants took aspirin, two took warfarin, four took an undetermined blood 
thinner, one took rivaroxabin (direct oral anticoagulant) and two did not take any blood thinner. 
Participant 03 admitted that the risks and benefits of taking a blood thinner medication was not 
offered to him by his doctor.  These numbers are concerning, as every patient with sustained AF 
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should be considered for anticoagulation medication to prevent stroke. While many recent 
sources seem to focus on the use of DOACs as best practice for anticoagulation, this research has 
found that some participants are still using warfarin.  Further education that target both 
healthcare providers and patients within rural communities are urgently needed and should be 
developed to address best practices with respect to OAC therapy as a means of improving the 
patient experiences and health outcomes.  
Limitations 
 This study has responded to a gap in knowledge and has exploring the experiences of 
patients that live with AF.  The qualitative approach has enabled an in depth analysis of patient 
experiences, which in turn has enabled the identification of some gaps and new lines of inquiry. 
Despite having many strengths, this research does also have limitations that are important to 
consider.  First, a key challenges that arose from this research was related to recruitment, in 
particular the failure to recruit participants from one of the smaller communities in northern 
British Columbia that we had initially targeted.  Though twelve interviews provided sufficient 
data to enable saturation, a sample from yielded some additional insights.   
 Second, I recruited participants using a convenience-criterion sample.  It is possible that 
this by recruiting participant with this method, the sample population may not be representative 
of the general population with AF in rural and remote communities (Loiselle & Profetto-
McGrath, 2011).  As previously highlighted, most of the participants were under seventy years of 
age, and greater recruitment of older adults may have provided different insights.  Third, 
qualitative studies provide an in depth exploration of phenomena, however, the findings are not 
considered generalizable in the traditional sense.  In congruence with the philosophical 
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underpinnings of qualitative research, the findings are transferable to those in similar contexts 
and in similar populations and have value in contributing the patient experience and voice. 
Finally, one limitation that affected my research and literature review was the change in 
guidelines for treating AF from the Canadian Cardiovascular Society.  The guidelines changed in 
2016, when I was in the midst of my research.  The update to guidelines focused on 
antithrombotic therapy, data with non-vitamin K antagonist oral anticoagulants, the use of 
antidotes for these anticoagulants, digoxin as a rate control agent, perioperative anticoagulation 
management and AF surgical therapy (Macle et al., 2016).  Particularly in regards to 
anticoagulation, DOACs are now becoming more commonly prescribed due to the introduction 
of a reversal agent in the instance of hemorrhagic bleeding (Almegren, 2017).  This change in the 
guidelines for stroke management required me to update the literature review, and look at my 
findings differently, as only one of my participants were prescribed and were taking a DOAC. 
However, despite this change, it is important to recognize that not all patients are being managed 
according to the best practice guidelines.  Aspirin therapy is still very common, as seen by the 
number of people taking these medications in this study, which suggests that many patients are 
not managed appropriately.  Further research that examines the longer-term impacts of these 
guidelines may provide useful insights and feedback on adherence to the most recent evidence 
based guidelines. 
 
Conclusion 
 AF is one of the most pervasive cardiac arrhythmias in world, at one percent of the 
worldwide population suffering with this life-limiting disease (Assiri et al., 2013).  Statistics and 
research have shown that AF is the most common arrhythmia in older adults aged eighty and 
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older, with a prevalence of nine percent of the total age group (Nantsupawat, Nugent & 
Phrommintikul, 2013).  By the year 2050, the incidence of AF in this group is thought to increase 
2.5 fold, with fifty percent of total AF sufferers predicted to be eighty or older (Nantsupawat et 
al., 2013).  This is a major public health crisis, as the treatment and management of stroke risk in 
this population can be complex due to other comorbities and fall risk (Nantsupawat et al., 2013).   
The qualitative analysis of the study data provided insight on where we as healthcare 
providers can improve in providing care to patients with AF in both rural and an urban settings.  
Foremost, health care providers must ensure that patients are fully informed on the risks and 
benefits of oral anticoagulation, and the important role that it plays in stroke prevention.  With 
three major themes emerging from the research: living with AF, stroke prevention and decision 
making, and navigation and access to health care, this insight into people living with AF can help 
guide future studies and educational endeavours.  The findings of this study concluded that 
people with AF would benefit overall from better education about this disease and the prevention 
of stroke, as anticoagulation at the fore front of stroke prevention, with perhaps a wide spread 
campaign focusing on educating the general public about AF.  Pulse checks should be a routine 
part of exams in doctors clinics to check for new onset irregular heartbeats in conjunction with a 
cardiac arrhythmia.  Most of all, education on the importance and initiation of oral 
anticoagulation for all people with AF (who meet the criteria for oral anticoagulation) is crucial 
to preventing stroke and maintaining quality of life.  This research helps to fill a gap previous 
unexplored, as there is very little data available on the topic of AF and stroke prevention in 
northern British Columbia as whole.  Overall, the findings of this study can be helpful in 
supporting the development of targeted education programs and initiatives for patients and 
providers, which in turn may improve the patient experience, satisfaction, and outcomes. 
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Appendix A 
 
CHADS2 scoring criteria 
 
 
Risk Factor Score 
Congestive cardiac heart failure 1 
Hypertension (consistentl 
y >140/90 mmHg or treated 
hypertension 
1 
Age ≥75 years 1 
Diabetes mellitus 1 
Stroke or transient ischaemic 
attack 
2 
Score 0-6 
 
Retrieved from: Richards, G. (2012). An overview of atrial fibrillation [Learning Zone: 
Cardiology]. Nursing Standard, 26(52), 47-56. 
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Appendix B 
CHA2DS2-VASc scoring criteria 
Risk Factor Score 
C Congestive heart failure 1 
H Hypertension 1 
A2 Age ≥ 75 years 2 
D Diabetes mellitus 1 
S2 Stroke or transient ischaemic 
attack 
2 
V Vascular disease (previous 
myocardial infarction, peripheral 
artery disease or aortic plaque) 
1 
A Age 65-74 1 
Sc Sex category (female) 1 
 
Retrieved from: Richards, G. (2012). An overview of atrial fibrillation [Learning Zone: 
Cardiology]. Nursing Standard, 26(52), 47-56. 
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Appendix C 
 
HASBLED Score 
 
Letters Clinical Characteristica Points Awarded 
H Hypertension 1 
A Abnormal liver and renal 
function (1 point each) 
1 or 2 
S Stroke 1 
B Bleeding 1 
L Labile INRs 1 
E Elderly (e.g. age > 65 years) 1 
D Drugs or alcohol (1 point 
each) 
1 or 2 
  Maximum 9 points 
 
• aHypertension’ is defined as systolic blood pressure >160 mmHg. ‘Abnormal kidney function’ is defined as the 
presence of chronic dialysis or renal transplantation or serum creatinine ≥200 µmol/L. ‘Abnormal liver 
function’ is defined as chronic hepatic disease (e.g. cirrhosis) or biochemical evidence of significant hepatic 
derangement (e.g. bilirubin >2 x upper limit of normal, in association with aspartate 
aminotransferase/alanine aminotransferase/alkaline phosphatase >3 x upper limit normal, etc.). ‘Bleeding’ 
refers to previous bleeding history and/or predisposition to bleeding, e.g. bleeding diathesis, anaemia, etc. 
‘Labile INRs’ refers to unstable/high INRs or poor time in therapeutic range (e.g. <60%). Drugs/alcohol use 
refers to concomitant use of drugs, such as antiplatelet agents, non-steroidal anti-inflammatory drugs, or 
alcohol abuse, etc. 
• INR = international normalized ratio. 
Retrieved from: Camm et al., 2010, p. 2385 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  128
 
Appendix D 
 
Classification of AF-related symptoms (EHRA Score) 
 
EHRA I No symptoms 
EHRA II Mild symptoms; normal daily activity not 
affected 
EHRA III Severe symptoms; normal daily activity 
affected 
EHRA IV Disabling symptoms; normal daily activity 
discontinued 
 
Retrieved from: http://www.chadsvasc.org/, (n.d.) 
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Appendix E 
 
List of search terms used and articles available in each database 
 
Number Search Term CINAHL PubMed 
1. Atrial Fibrillation 18,576 52,466 
2. Ablation 13,105 66,334 
3. Ischemic stroke 7,684 61,227 
4. Northern British Columbia 291 1,093 
6. Paroxysmal atrial fibrillation 1,142 6,284 
7. Antithrombotic 2,806 12,726 
8. Rural health care access 6 5107 
9. Rural health care 559 32,701 
10. Nonadherence to medication 
regimen 
1 246 
11. International normalized ratio 3,022 7,201 
12. Novel oral anticoagulants 101 1,084 
13. Anticoagulants 10,558 191,387 
14. Lone AF 418 489 
15. AF AND stroke risk factor 760 5007 
16. Antithrombotic therapy AND 
noncompliance 
31 92 
17. 1 AND 13 2,388 7,375 
18. 1 AND 8 1 3 
19. 1 AND 10 1 0 
Data retrieved from the University of Northern British Columbia’s library website 
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Appendix F 
Thesis Timeline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activity/Mon
th 
Dec/1
5 
Jan/1
6 
Feb/1
6-
Feb/1
7 
Mar/1
7-
Sept/ 
17 
Jul/17 Aug/
17-
Jan/ 
19 
Mar/ 
19 
Editing Thesis 
Proposal 
       
Determining thesis 
proposal committee 
       
Defense of thesis 
proposal 
       
Creating research 
questionnaire  
       
Requesting ethical 
approval from UNBC 
to conduct research 
 
 
      
Requesting ethical 
approval from 
Northern Health 
Research Review 
Committee to 
conduct research 
       
Requesting 
permission to collect 
data from patients at 
the Central Square 
Medical Clinic in 
Smithers, B.C. 
       
Collecting data from 
participants from 
medical clinics in 
northern British 
Columbia 
       
Disseminating data 
findings with 
thematic analysis 
       
Writing research 
findings into thesis 
and editing 
       
Thesis Defense        
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Appendix G 
Literature Review Articles 
 
Type of Article Number used in Literature Review 
Reviews 4 
Cohort 1 
Qualitative Descriptive 1 
Cross-sectional survey 1 
Analysis 1 
Non-randomized retrospective follow-up 
analysis 
1 
Prospective descriptive 2 
Systematic reviews 3 
Program evaluation 1 
Longitudinal cohort 1 
Observational study 1 
Representative national survey 1 
Descriptive retrospective explorative design 1 
Comparative study 1 
Descriptive cross-sectional design 1 
Straight line analysis 1 
Survey with in-depth semi-structured 
interviews 
1 
Single center, retrospective analysis 1 
Population based study 1 
Questionnaire 1 
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Appendix H 
 
Participants’ Data 
Table 
 
 
Participant 01 02 03 04 05 06 
Age 
Mean age= 60.83 
58 74 39 74 55 69 
Reported 
anticoagulant 
200 mg ASA Warfarin Not offered by 
doctor 
Takes blood 
thinner 
Warfarin Aspirin 
Length of AF “couple of 
years” 
Six years ago 10-15 years 1 year 1.5 years 34 years 
Consent Yes Yes Yes Yes Yes Yes 
Symptomatic Yes Yes Yes Yes Yes (reported 
no) 
No 
Gender Male Male Male Male Female Male 
Refused warfarin Yes No Yes Not stated No Yes (negative 
reaction) 
Frequency of 
bloodwork 
Every three 
months 
Not stated Every five years 
and PRN 
Every other 
week 
Every two weeks “Virtually never” 
Participation in 
outdoor 
recreational 
activities 
Not stated Not stated Yes- hunting No- walking, 
working 
Likes bike 
riding, walking, 
gardening 
Canoeing all 
major rivers 
going into arctic 
ocean 
Accessed 
emergency 
treatment for 
initial 
diagnosis(yes/no) 
No (found 
during annual 
physical) 
No (saw 
cardiologist in 
office) 
Yes Yes Yes No (diagnosed 
during annual 
physical) 
 
Participant 07 08 09 10 11 12 
Age 
Mean age= 60.83 
37 56 69 79 67 53 
Reported 
anticoagulant 
No Yes Yes- Gets 
bloodwork for 
his anticoagulant 
Yes Rivaroxaban  80 mg ASA  
Length of AF 15 years 
approximately 
2 years 6 years “Many years 
ago” 
Twenty-seven 
years 
Seven years 
Consent Yes Yes Yes Yes Yes Yes 
Symptomatic Yes Yes Yes Yes Yes No 
Gender Male Male Male Female Male Male 
Refused warfarin Refused all 
anticoagulation 
or medications 
Not stated No Not stated No (he is happy 
with whatever 
medication his 
doctor 
prescribes) 
No 
Frequency of 
bloodwork 
PRN- every 
couple of years 
Every couple of 
weeks 
Every three 
weeks if stable, 
otherwise every 
two weeks 
Once per month Not stated Every six 
months 
Participation in 
outdoor 
recreational 
activities 
Plays hockey Hunting, hiking, 
baseball, two 
dogs 
Not stated No Not stated Likes hiking, and 
rock collecting 
Accessed 
emergency 
treatment for 
initial 
diagnosis(yes/no) 
Yes Yes Yes Yes Yes Yes 
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Appendix I 
 
Invitation Letter for Study Participant 
 
 
 
Date 
 
Dear Sir/Madam, 
 
RE:  The Understanding and Management of Stroke Risk in patients with Atrial 
Fibrillation in northern British Columbia 
 
My name is Ali Marleau and I am a Registered Nurse and a graduate student in the school of 
Nursing at the University of Northern British Columbia.  As part of my thesis, I am conducting a 
research study investigating patients’ who have atrial fibrillation (irregular heart beat) and their 
understanding and management of stroke risk in northern British Columbia.  Under the 
supervision of Dr. Davina Banner (Ph.D, Associate Professor at UNBC), I am looking to recruit 
participants from your doctor’s clinic who have been diagnosed with atrial fibrillation.  We are 
writing to introduce ourselves and to invite you to be part of this interesting study. 
 
Invitation: 
 
Your doctor identified you as someone that would be able to provide useful information and we 
would like to invite you to participate within this study.  The study will involve a telephone 
interview or face to face interview lasting approximately 30-60 minutes in duration.  This will be 
arranged at a time convenient to yourself.  In the interview, we will ask you about how you 
understand and manage your risk for stroke, and your experience living with atrial fibrillation.  
We are hoping to understand more about the patients’ perspective and how we as healthcare 
providers can help patients best to decrease their risk for stroke. 
 
Please read through the attached information sheet.  Dr. Banner or I will contact you by 
telephone this week to introduce ourselves personally and to answer any questions.  If you wish 
to be involved, we can make an appointment at that point.  If you do not wish to participate in 
this research study, please send an email to marleaua@unbc.ca or call 250-877-7158 to be 
removed from the call list.  Participation in this research is voluntary and all information will be 
confidential.  Your care will not be affected in anyway should you choose not to be involved.  
 
We hope that you will consider taking part in this interesting study and should you have any 
further questions please do not hesitate to call 250-877-7158 or email marleaua@unbc.ca. 
 
Yours sincerely, 
 
  134
Ali Marleau 
Principle Investigator 
marleaua@unbc.ca 
 
Encs:Participant information sheet and consent form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  135
Appendix J 
 
Participant Information Letter/Consent Form (Five pages) 
 
 
 
Information Letter/Consent Form 
The understanding and management of stroke risk in patients with atrial 
fibrillation in rural northern British Columbia 
Date 
Dear: Sir/Madam, 
Who is conducting the study? 
Study team members: 
Faculty Researcher:  
Dr. Davina Banner 
Associate Professor & Coordinator of Undergraduate Programs 
TAL-1526 
School of Nursing 
University of Northern British Columbia 
3333 University Way 
Prince George, British Columbia 
Canada 
V2N 4Z9 
Phone: 250-960-5259 
Fax: 250-960-6410 
 
Student Researcher: 
Alexandra (Ali) Marleau 
Graduate Student 
School of Nursing, Master of Science in Nursing 
Phone: 250-877-7158 
Email: marleaua@unbc.ca 
Supervisor: Dr. Davina Banner, Associate Professor & Coordinator of Undergraduate Programs 
Supervisor’s office telephone number: 250-960-5259 
Supervisor’s email: bannerl@unbc.ca 
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Invitation and Purpose of the Project 
The purpose of this study is to investigate patients’ understanding and management 
of stroke risk who have been diagnosed with atrial fibrillation (irregular heart 
beat).  We also want to gain perspective on the patients’ experience of living with 
atrial fibrillation.  You are being invited to participate because you have been 
identified by your family doctor as a person who has a diagnosis of atrial 
fibrillation (irregular heart beat). 
 
The Researchers 
Under the supervision of Dr. Davina Banner (RN, PhD), Associate Professor in the 
School of Nursing at the University of British Columbia, I (Ali Marleau, RN) am 
researching the understanding and management of patients diagnosed with atrial 
fibrillation and their understanding of stroke risk in rural communities in northern 
British Columbia, as part of my thesis.  Dr. Davina Banner has worked extensively 
in the field of cardiac research rural health delivery. 
 
Participation in the Project is not mandatory 
Participation in this study is completely voluntary, and are in no way obligated to 
participate.  You may withdraw at any time during the process.  You can choose to 
refuse to answer any questions that make you uncomfortable without giving a 
reason.  If you choose to withdraw from the study, any information we have 
collected will be withdrawn and securely destroyed, unless you consent to your 
information being retained and analyze.  If you do not wish to participate, your 
care will not be affected in any way. 
 
What will happen during the project? 
If you choose to participate in this study, you will be interviewed via telephone or 
face to face approximately 30-60 minutes in duration, if you decide to take part in 
this research study.  This will be arranged at a time convenient to yourself.  In the 
interview, we will ask you about how you understand and manage your risk for 
stroke, and your experience living with atrial fibrillation.  We are hoping to 
understand more about the patients’ perspective and how we as healthcare 
providers can help patients best to decrease their risk for stroke. 
 
What should I do if I choose to participate in this project? 
If you choose to participate in this project, we will contact you with further 
information, or if you have additional questions you may call us at either 250-877-
7158 or 250-960-5259.  If you agree to participate, we ask that you provide 
consent either verbally over the telephone verbally or in writing.   
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What if I do not want to participate in this study? 
We completely understand if you do not wish to participate in this study.  Please 
call us at 250-877-7158 or email at marleaua@unbc.ca to let us know that you do 
not want to participate in this study. 
 
Has this project received funding? 
This project has not received any funding.  No financial rewards will be offered if 
you choose to participate. 
 
What are the potential advantages/disadvantages to participating in this 
study? 
By participating in this study, you can help to increase the information about what 
it is like to live with atrial fibrillation, a topic that is not well explored. Some 
people may find discussing their thoughts and feelings in a confidential setting 
helpful. 
Disadvantages to participating can include bringing up upsetting thoughts while in 
the interview.  Some people find talking about their experience distressing.  You 
are not obligated to talk about anything difficult to you, and you may stop the 
meeting at any point.  If any information discussed may indicate a serious health 
problem or illness, we will let you and your doctor know.   
 
What if I have questions about the study? 
If you have any questions about the study, please contact myself at 
marleaua@unbc.ca or 250-877-7158 or Dr. Davina Banner at 250-960-5259 or 
bannerl@unbc.ca.   
 
Who can you contact if you have complaints or concerns about the study? 
If you have any concerns or complaints about your rights as a research participant 
and/or your experiences while participating in this study, contact the UNBC office 
of Research at 250-960-6735 or by email at reb@unbc.ca. 
 
What about confidentiality/anonymity/data storage? 
The interviews will be recorded verbatim with a recording device, and then stored 
securely using encrypted files on a password protected computer.  You will remain 
anonymous in all written materials.  However, confidentiality cannot be guaranteed 
to participants as personal stories may identify them in a small town.  Only the 
investigators of the study have access to this information.  All data will be stored 
securely for five years.  All data will be destroyed after this five year period. 
 
Where will the study results be available? 
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The results of this study will be reported in a graduate thesis and may also be 
published in journal articles and books.  If you wish to receive a copy of the 
completed thesis, please leave your email address or mailing address on the 
consent form in the designated area. 
 
Thank you for your time in reading this information sheet.  Please contact us with 
any questions regarding this project. 
 
 
 
 
 
 
 
 
 
Participant Consent and Signature Page 
Taking part in this study is entirely up to you.  You have the right to refuse to 
participate in this study.  If you decide to take part, you may choose to pull out of 
the study at any time without giving a reason and without any negative impact on 
your medical care. 
• Your signature below indicates that you have received a copy of this consent 
form for your own records. 
• Your signature indicates that you consent to participate in this study. 
 
____________________________________                    ____________________ 
Participant Signature                                                           Date 
(or Parent or Guardian Signature) 
 
____________________________________ 
Printed Name of the Participant (or Parent or  
Guardian) signing above 
If you would like a copy of the completed thesis, please leave your mailing address 
or email address 
here:______________________________________________________________
__________________________________________________________________
__________________________________________________________________ 
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Please mail this signed participant consent and signature form in provided 
envelope addressed to Dr. Davina Banner if you wish to take part in this research 
study. Postage is included on envelope. 
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Appendix K 
 
Physician Recruitment Letter (Two pages) 
 
 
The understanding and management of stroke risk in patients with atrial fibrillation in 
rural northern British Columbia 
21st January 2017 
Dear: [CLINICIAN’S NAME] 
My name is Ali Marleau and I am a Registered Nurse and a graduate student in the school of 
Nursing at the University of Northern British Columbia.  As part of my thesis, I am conducting a 
research study investigating patients’ who have atrial fibrillation (irregular heart beat) and their 
understanding and management of stroke risk in northern British Columbia.  Under the 
supervision of Dr. Davina Banner (Ph.D, Associate Professor at UNBC), I am looking to recruit 
participants from your medical clinic who have been diagnosed with atrial fibrillation.   
The proposed study aims to explore the experience of patients with AF who live in rural and 
remote areas of northern British Columbia using a qualitative descriptive approach.  The study 
seeks to understand their perceptions of stroke risk and their decision making regarding stroke 
risk management.  The study is guided by the following questions and sub-questions: 
Research question: How do patients in rural northern British Columbia with AF understand 
and manage their risk of stroke? 
• What are the experiences of patients living with AF and risk of ischemic strokes 
secondary to AF in rural and remote areas of Northern British Columbia? 
• What factors influence patients’ decision making around stroke prevention? 
The study will involve a telephone interview or face to face interview lasting approximately 30-
60 minutes in duration.  This will be arranged at a time convenient to the participant.  In the 
interview, we will ask the participant about how they understand and manage their risk for 
stroke, and their experience living with atrial fibrillation.  We are hoping to understand more 
about the patients’ perspective and how we as healthcare providers can help patients best to 
decrease their risk for stroke. 
If you are agreeable, we are asking if you can identify 10-15 potential participants that we can 
recruit for our study from your patients.  Our inclusion criteria for participants are (i) have a 
diagnosis of atrial fibrillation; (ii) live in a rural or remote community in northern British 
Columbia.  We will give identified participants a package of information, which I will provide to 
you with this letter: 
• The invitation letter to participants 
• The interview schedule 
• The information/consent letter 
• My thesis proposal 
 
If you have any questions, please contact Davina or myself.  Thank you for your time! 
Sincerely, 
Ali Marleau 
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Faculty Researcher:  
Dr. Davina Banner 
Associate Professor & Coordinator of Undergraduate Programs 
TAL-1526 
School of Nursing 
University of Northern British Columbia 
3333 University Way 
Prince George, British Columbia 
Canada 
V2N 4Z9 
Phone: 250-960-5259 
Fax: 250-960-6410 
 
Student Researcher: 
Alexandra (Ali) Marleau 
Graduate Student 
School of Nursing, Master of Science in Nursing 
Phone: 250-877-7158 
Email: marleaua@unbc.ca 
Supervisor: Dr. Davina Banner, Associate Professor & Coordinator of Undergraduate Programs 
Supervisor’s office telephone number: 250-960-5259 
Supervisor’s email: bannerl@unbc.ca 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
\ 
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Appendix L 
 
Study Interview Questions 
 
AF Study Interview Questions 
Alexandra Marleau 
 
• Can you tell me about the first time you experienced an irregular heartbeat?   
o If they did not experience an irregular heart beat: what were your symptoms of AF?) 
 
• What might made you seek emergency treatment? 
 
• What are your experiences of living with atrial fibrillation? 
 
• What kinds of services and treatments have you received? 
 
• What do you consider some of the biggest concerns relating to AF? 
 
• Atrial fibrillation is linked to a risk of stroke. What is your understanding of this? 
o Do you take an anticoagulant or blood thinner? 
o If so, how often do you get blood work done? 
 
• Can you tell me about the decision to start or not start an anticoagulant? 
 
• Has anything in your life changed since getting diagnosed with AF? If so, how. 
 
• Have you experienced challenges in accessing healthcare services relating to your AF 
o Prompt: Have you ever travelled to access health care services as a result of your 
AF? 
• What resources or services have been most helpful/least helpful? 
 
• What do you think other patients should know about this condition? 
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Appendix M 
 
Conceptual Map 
 
 
